CN101336256B - A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions - Google Patents

A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions Download PDF

Info

Publication number
CN101336256B
CN101336256B CN2006800519727A CN200680051972A CN101336256B CN 101336256 B CN101336256 B CN 101336256B CN 2006800519727 A CN2006800519727 A CN 2006800519727A CN 200680051972 A CN200680051972 A CN 200680051972A CN 101336256 B CN101336256 B CN 101336256B
Authority
CN
China
Prior art keywords
polymkeric substance
solution
medicine
nipam
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800519727A
Other languages
Chinese (zh)
Other versions
CN101336256A (en
Inventor
阿南德·C·比尔曼
拉马·慕克吉
迪拉杰·哈塔尔
桑乔伊·穆利克
马努·贾吉
马诺伊·库马尔·辛格
穆凯什·库马尔
迪帕克·普鲁什蒂
帕万·库马尔·古普塔
拉延德兰·巴威
绍布希特·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresenius Kabi Oncology Ltd
Original Assignee
Dabur Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Pharma Ltd filed Critical Dabur Pharma Ltd
Publication of CN101336256A publication Critical patent/CN101336256A/en
Application granted granted Critical
Publication of CN101336256B publication Critical patent/CN101336256B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/56—Acrylamide; Methacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/04—Anhydrides, e.g. cyclic anhydrides
    • C08F222/06—Maleic anhydride
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/10—Esters
    • C08F222/12—Esters of phenols or saturated alcohols
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/06—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C08F226/10—N-Vinyl-pyrrolidone
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
    • C08F222/36—Amides or imides
    • C08F222/38—Amides
    • C08F222/385—Monomers containing two or more (meth)acrylamide groups, e.g. N,N'-methylenebisacrylamide

Abstract

The invention relates to a biocompatible, non-biodegradable, and non-toxic polymer of formula (I), comprising of three monomeric units, selected from 1-Vinylpyrrolidone (VP), N-Isopropylacrylamide (NIPAM), and ester of Maleic anhydride and Polyethylene glycol (MPEG), cross-linked with a bi-functional vinyl derivative, of high purity and substantially free of respective toxic monomeric contaminants, and a process for preparation thereof. The invention further relates to nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds comprising the polymer of the invention, which are safe, less-toxic and convenient for bedside adminstration to patients in need thereof. Furthermore, the invention relates to a highly selective method for preparation of nanoparticulate pharmaceutical compositions of poorly water-soluble drugs or compounds.

Description

The biocompatible non-biodegradable nontoxic polymer that is used for nanoparticle pharmaceutical compositions
Technical field
Biocompatible and the non-biodegradable polymkeric substance that the present invention provides high purity, be substantially free of monomer impurity with and preparation method thereof.
The present invention also provides medicine or the pharmaceutical composition of compound of the poorly water-soluble of the form of nanoparticles of utilizing polymkeric substance according to the invention.
In addition, the invention still further relates to the poorly water-soluble that is used to prepare form of nanoparticles medicine or compound pharmaceutical composition high selective method and to the method for patient's applying said compositions that needs are arranged.
Therefore polymkeric substance of the present invention is nontoxic and safe, makes also that the nanoparticle pharmaceutical compositions toxicity of medicine or compound of the poorly water-soluble that contains said polymkeric substance is lower and use safer.
Background technology
In recent years, no matter as prosthese or be used to be designed to and the contacted medical treatment device of living body biological environment, the application of novel material in medical science or pharmaceutical field attracts people's attention just day by day.In these materials, polymkeric substance (main synthetic polymer) be find so far bring the most diverse kind of considerable benefit for patient's health care.
Polymkeric substance is widely used in medical science and pharmaceutical field.In medical field; Polymkeric substance is used as implant or propping material such as artificial organs, artificial blood vessel (vascular graft), intraocular lens (intraocular lense), joint prosthesis, breast prosthesis, suture material, external treatment, or other propping material for example is used for blood perfusion, blood oxygenator, conduit, transducer potector (blood tubing), wound and burn cover stock material, clamping plate, contact lenses etc. those.In pharmaceutical field, polymkeric substance has been particularly useful in the exploitation of nano particle delivery system and sustained release delivery system.Also carrying out extensive studies so that medicine is targeted to desired position with delivery system.In addition, found that polymkeric substance is very big in other purposes of using in for example transdermal drug delivery patch agent, microballoon, biological processing such as enzyme and the cell fixation etc.
In these are used; Study the nano particle drug delivery system more widely and studied the pharmaceutical carrier of the nanometer size on possess hydrophilic property surface widely, especially contained the spherical concentric zones of two polymer micelles (being responsible for the tight compression nuclear of the hydrophobic material of embedding hydrophobic drug or compound) and those of the shell processed by hydrophilic material.Find that these systems can escape by reticuloendothelial system (RES) identification and picked-up and therefore can in blood, circulate for a long time.In addition, (polymer micelle is made up of a hundreds of segmented copolymer usually and diameter is that about 20nm～50nm), said particle oozes out at pathogenic site such as solid tumor place through passive target mechanism owing to their minimum sizes.
The chemistry of polymkeric substance and constitutional features have determined their characteristic.Polymer chain can be straight chain, side chain basically or be linked on the contiguous chain.In addition, these chains can be unordered, orderly or be oriented on the direction.These constitutional featuress combine with chemical constitution, have brought multifrequency nature to polymkeric substance, have produced the application that use at multiple terminal.And these and chemical constitution structure combining characteristic can give or deprive the biocompatibility of resulting polymers and to by the caused biodegradable resistance of host tissue environment.These factors also influence other characteristic such as solubleness and processing and forming method.
In addition; When with polymer injection in Mammals the time; It disappears from site of administration usually lentamente, yet this disappears and takes place in response to chemical reaction such as hydrolysis (it is the part of biotransformation normally) and said polymkeric substance is eliminated through metabolism and from body.Yet this produces unwanted metabolite sometimes, and said metabolite has side effects to multiple biosystem.Therefore, based on the function of expection, inertia in environment/to the environment for use inertia and from the complete elimination of site of administration or absorption and basically as the speed limit barrier possibly being most important from its transportation and the polymkeric substance that discharges medicine.In addition, the biological degradability of polymkeric substance depends on the mechanical properties and the chemical property of polymkeric substance.Multiple natural, synthetic and biosynthetic polymkeric substance is biodegradable and degraded by environment.It is biodegradable to tend to right and wrong based on the polymkeric substance of C-C skeleton, has biodegradable and contain heteroatomic polymer backbone.Therefore, can connecting for example through the deletion/interpolation chemistry of wisdom, anhydride bond, ester bond or amido linkage etc. be designed into non-biodegradable/biodegradable in the polymkeric substance.Wherein, the common instance of non-biodegradable polymers material comprises plastic of poly vinyl acetate, YSR 3286, Texin 5590, TKK 021, FM, Vilaterm and SE.
About in the effort of being done aspect the nano particle delivery system of the multiple medicine of development and use polymkeric substance a large amount of available reports being arranged nearest decades.Only lift several examples, it comprises following disclosure:
I) people's such as Sakurai US 5,412,072 wherein finds to contain mixture with the medicine of polymkeric substance covalent bonding and makes said mixture water soluble and therefore be suitable for using, and said polymkeric substance is made up of wetting ability fragment and hydrophobicity fragment.The normally water-soluble relatively poor or water-fast compound of wherein used medicine, and it is reported that said drug-polymer mixture forms polymer micelle and becomes water-soluble polymer polymeric drug available and that be suitable for using in the aqueous solution.
Ii) people's such as Yokoyama US 5,449,513; Wherein their report and people such as Sakurai be at US 5,412, disclosed difference in 072; Wherein polymer micelle is not the mixture of its Chinese traditional medicine and polymkeric substance covalent bonding, but its Chinese traditional medicine is embedded in the mixture in the polymkeric substance.The character of used embedding medicinal is hydrophobic.The method of utilization routine successively is for example ultrasonic to be embedded in hydrophobic drug in the polymer shell, and the micella that obtains thus through the dialysis purifying subsequently prepares polymer micelle.
Iii) people's such as Desai US 5,439,686, US 5,362,478, US 5,916,596, US6,096,331, US 6,537,579 and US 6,749,868, wherein prepared the polymer micelle of water-fast compound basically.It is reported that said water-fast compound is embedded in the polymer shell to a great extent and is suitable for using to the patient of needs with dissolving or suspendible form.
People such as Sakurai are at US 5,412, in 072 used polymkeric substance normally contain the wetting ability fragment that is selected from polyoxyethylene glycol, polysaccharide, SEPIGEL 305 etc. and the hydrophobicity that is selected from SAP 73, polyglutamic acid, polylysine etc. segmental those.
People such as Yokoyama are at US 5; In 449,513 used polymkeric substance normally contain the wetting ability fragment that is selected from polyethylene oxide, polymalic acid, SAP 73, polyglutamic acid, polylysine, polysaccharide etc. and be selected from gather (L-aspartic acid β-benzyl ester), gather (L-glutamic acid, gamma-benzyl ester), gather (aspartate of beta substitution), gather (γ-substituted glutamate), gather (L-leucine), gather (L-Xie Ansuan), gather (L-phenylalanine(Phe)), the hydrophobicity of hydrophobicity polyamino acid, PS, Rohm tech inc, polyacrylic ester, Rohm tech inc acid amides (polymethacrylate amide), ROHM esteramides (polyacrylate amide), polymeric amide, polyester, polyalkylene oxide and hydrophobic polyolefin segmental those.
People such as Desai are at US 5,439, and 686, US 5,362; 478, US 5,916, and 596, US6,096; 331, US 6,537,579 with US 6; Used polymkeric substance normally contains those of sulfydryl or disulfide linkage, for example BSA (it contains 35 cysteine residues), Regular Insulin (it contains 6 cysteine residues), oxyphorase (its each α in its structure basically in 749,868 2β 2Contain 6 cysteine residues in the unit), N,O-Diacetylmuramidase (it contains 8 cysteine residues), Tegeline, α-2-macroglobulin, VN, VN, Fibrinogen etc.These polymkeric substance are crosslinked basically through forming disulfide linkage.These polymkeric substance comprise foregoing synthetic polymer and the natural polymer that in its structure, has sulfydryl or disulfide linkage.It is reported said sulfydryl or disulfide linkage or be pre-existing in or obtain through suitable chemically modified.It is reported that natural polymer is preferred and comprises albuminous protein employed, oligopeptides, polynucleic acid etc.
Yet what the shortcoming of disclosed polymer micelles such as Sakurai etc., Yokoyama etc. and Desai was that their use all is biodegradable polymkeric substance (synthetic and natural).Can influence the release dynamics of drug release pattern and institute's carrying medicament though should also be mentioned that biodegradable polymers, yet it is not that drug delivery system is preferred especially, because they:
A) owing to promptly being had the low blood plasma life-span by the cell capture of monokaryon macrophage system (MPS);
B) lack response to physiological change;
C) lack the constant drug release kinetics, its possibly cause medicine economically with treatment on waste and other spinoff; With
D) can cause toxicity or immunogenic increase, because the embedding of pharmaceutical grade protein relates to organic solvent, said organic solvent can cause protein denaturation.
Used and disclose the delivery system of non-biodegradable polymers through following document:
I) people's such as Maitra US 5,874,111, its Chinese traditional medicine is embedded in the polymkeric substance, causes forming highly monodispersed polymkeric substance hydrophilic nanoparticles.Used polymkeric substance is to contain monomer such as vinyl pyrrolidone (VP) or vinyl pyrrolidone and the mixture that gathers fumaric acid glycol ester (PEGF) etc.
Ii) people's such as Maitra US 6,322,817, wherein used polymkeric substance contains the amphipathic monomer that is selected from following material of at least a type: vinyl pyrrolidone, vinylformic acid, chain length are C 3To C 6Alkyl acrylate, the chain length of functionalized poly (ethylene glycol) (molecular weight 2000 to 6000) be C 3To C 6N-alkyl acrylamide and chain length be C 3To C 6The alkyl cyanoacrylate.The medicine that is embedded in the polymer micelle is Taxan (taxane) verivate, especially a taxol.Iii) people's such as Lowe US 2005/0169882, wherein used polymkeric substance contains intelligent fragment (it is for non-biodegradable) and biodegradable fragment.More specifically; Said intelligence, non-biodegradable fragment contain and gather (N-NSC 11448), gather (N-alkyl acrylamide), gather (N-n-propyl acrylic amide), gather (N-isopropyl methyl acrylic amide), gather (oxyethane)-gather (propylene oxide)-gather (oxyethane), elastin-like polypeptide, or derivatives thereof; Said biodegradable fragment contains polysaccharide, Expex, polyester, POLYACTIC ACID (polylactide), gathers (L-lactic acid), gathers (D, L-lactic acid), gathers (lactide-co-glycolide), biotinylated (terepthaloyl moietie-lactic acid) segmented copolymer etc.
At US 5,874, in the situation of 111 disclosed polymkeric substance, should be understood that these polymkeric substance prepare through monomeric polymerization separately, and the polymer materials that obtains thus through dialysis method from the water-bearing media that contains this polymer materials purifying with separate.
At US 6,322, in the situation of 817 disclosed polymkeric substance, said polymkeric substance prepares through monomeric polymerization separately, and through dialysis method from water-bearing media purifying with separate.
Equally, people such as Lowe also is through dialysis method purifying and isolating from the water-bearing media that contains said polymkeric substance at US 2005/0169882 disclosed polymkeric substance.
About disclosed compound or medicine in this article in US 5,874, the 111 disclosed polymkeric substance that are embedded in people such as Maitra, they mainly are antigen, Ox blood serum etc.At US 6; In 322,817 the situation, if be embedded in the water-fast Taxane derivative of drug main in the disclosed polymkeric substance of this article; Especially taxol, people such as Lowe then disclose the multiple medicine that is embedded in the disclosed polymer shell of this article in US 2005/0169882.
Further connect saidly, people such as Burman are at US 6,365, and 191 have instructed and contain US6, the pharmaceutical composition of disclosed polymkeric substance in 322,817, and more specifically instructed the especially pharmaceutical composition of taxol of Taxane derivative.In this article, through being joined in the infusion carrier that contains dextrose solution, the solution of taxol in ethanol prepared said pharmaceutical composition, added the aqueous solutions of polymers that contains AS and buffer reagent in the said infusion carrier.People such as Burman claim also that said pharmaceutical composition is stable and surpass 12 hours and have no medicine from said infused fluid, to be precipitated out, and claim in addition the said infused fluid of preparation after 24 hours more than 90% the medicine of (like what HPLC analyzed) be embedded in the polymer micelle.
Although people such as Burman are at US 6,365, claim that wherein disclosed pharmaceutical composition is a form of nanoparticles in 191, yet in specification sheets, do not mention the size of the form of nanoparticles of being claimed.Unique narration of the particle size of the relevant polymer micelle that contains taxol is found in people such as Maitra at US 6,322, in the 817 disclosed contents, reports that wherein the said diameter range that contains the nano particle of taxol is 30～150nm.Equally, people such as Lowe does not mention the particle size of polymer micelle yet in US 2005/0169882 disclosed content.
Be necessary to point out that US 5,874,111, disclosed polymkeric substance is to be prepared by one or more monomers that comprise vinyl pyrrolidone and N-NSC 11448 among US 6,322,817, US 6,365,191 and the US2005/0169882.Also be necessary to point out; Vinyl pyrrolidone and N-NSC 11448 are toxic chemicals; Its existence in pharmaceutical composition means not only for the consumption of humans and can not be ratified by worldwide hygiene department, but also will meet the strict quality regulation with strict limit that international pharmacopoeias forum is proposed.For example; According to US and European officinal regulation, said polyvinyl pyrrolidone polymers and contain vinyl pyrrolidone and should not surpass 0.001% limit (promptly＜10ppm) as the level of the monomer vinyl pyrrolidone in monomeric any other polymkeric substance.
At US 5; 874,111, US 6,322; 817, US 6; 365,191 prepare with separating with being used to described in the US 2005/0169882 and to utilize vinyl pyrrolidone to have very big danger as the method for the polymkeric substance of one of monomer, and said monomer is that vinyl pyrrolidone possibly exist (promptly＞10ppm) to be higher than 0.001% limit.
Comprise this vinyl pyrrolidone that utilizes and have same big danger as the pharmaceutical composition of the polymkeric substance of one of monomer; Said pharmaceutical composition also possibly contain the vinyl pyrrolidone as monomer impurity, and said monomer is that vinyl pyrrolidone also possibly exist (promptly＞10ppm) to be higher than 0.001% limit.
For US 6,322,817, disclosed pharmaceutical composition among US 6,365,191 and the US 2005/0169882, situation is especially true.
Needn't overemphasizedly be that always staying one or more reactants means that any chemical reaction comprises that the reaction for preparing polymkeric substance all will never be completely in the product.Be applied to comprise vinyl pyrrolidone as in the monomeric polyreaction and depend on the mol ratio or the weight ratio of used vinyl pyrrolidone, possible is that a certain amount of vinyl pyrrolidone will be retained in by in its prepared polymerisate as impurity.
With above relevant be to have been found that the inventor's worry is a necessary being.Through to accurately according to US 6; Three kinds of monomers described in 322,817 example I, II and the III be vinyl pyrrolidone (VP), N-NSC 11448 (NIPAM) and maleic anhydride and polyoxyethylene glycol ester (MPEG) polymerization and the analysis of the polymkeric substance for preparing finds that it contains a certain amount of N-NSC 11448 (NIPAM) and the vinyl pyrrolidone (VP) of concluding just like Table I.
Table-I: according to US 6,322, the amount of residual monomer in the polymkeric substance of the preparation of method described in 817 example I, II and the III
Monomer Detected %w/w in polymkeric substance
NIPAM 0.066-0.076(660-760ppm)
VP 0.008-0.011(80-110ppm)
The amount of the vinyl pyrrolidone that very is apparent that in polymkeric substance to be found is 0.001% more than 8 times of toxic limit (being 10ppm) at least, and it will be very dangerous and highly toxic that the pharmaceutical composition that wherein contains such polymkeric substance is used to use to the mankind or animal.
Though it is nonessential; But still need be substantially free of the polymkeric substance of toxicity monomer such as N-NSC 11448 (NIPAM) and vinyl pyrrolidone (VP), also need comprise the pharmaceutical composition of the polymkeric substance that is substantially free of toxic monomer impurity such as N-NSC 11448 (NIPAM) and vinyl pyrrolidone (VP).
Should also be noted that to it is reported people such as Burman at US 6,365, disclosed pharmaceutical composition only had about 12 hours or more stability in 191, and when finishing in 24 hours 90% or above medicine be embedded in the polymer micelle.In addition, it is reported people such as Lowe in US2005/0169882 disclosed pharmaceutical composition under the situation of several hours release of bioactive substances in up to several days to the load of biologically active substance about only 40%.
Further exist having the longer stability and the demand of the less pharmaceutical composition of high drug load and safety and toxicity more.
The present invention not only provides the polymkeric substance that is substantially devoid of poisonous monomer impurity, and provides to comprise and thisly use safety and have the pharmaceutical composition of the desired polymkeric substance of longer stability for humans, therefore is a much progress in this respect.
Goal of the invention
An object of the present invention is to provide highly purified physiologically acceptable and the non-biodegradable polymkeric substance that is substantially free of monomer impurity.
Another object of the present invention provides and is used to prepare the highly purified physiologically acceptable of monomer impurity and the method for non-biodegradable polymkeric substance of being substantially free of.
Another purpose of the present invention provides medicine or the pharmaceutical composition of compound of the poorly water-soluble of the form of nanoparticles that comprises highly purified and the physiologically acceptable and the non-biodegradable polymkeric substance that are substantially free of monomer impurity.
Another object of the present invention provides the method for pharmaceutical composition of medicine or the compound of the poorly water-soluble that utilizes highly purified and the physiologically acceptable and the non-biodegradable polymer manufacture form of nanoparticles that are substantially free of monomer impurity.
Another purpose of the present invention provides and comprises highly purified and do not contain medicine or the nanoparticle pharmaceutical compositions of compound of poorly water-soluble of physiologically acceptable and the non-biodegradable polymkeric substance of monomer impurity, and said pharmaceutical composition safety and toxicity are less.
Another object of the present invention provides the high selective method of the pharmaceutical composition that is used to prepare form of nanoparticles, and said pharmaceutical composition comprises medicine or compound and the high purity of poorly water-soluble and do not contain the physiologically acceptable and the non-biodegradable polymkeric substance of monomer impurity.
Another purpose of the present invention provides to having the patient who needs to use to comprise highly purified and being substantially free of the method for nanoparticle pharmaceutical compositions of physiologically acceptable and the non-biodegradable polymkeric substance of monomer impurity.
Another object of the present invention provides and comprises highly purified and do not contain the physiologically acceptable of monomer impurity and the nanoparticle pharmaceutical compositions of non-biodegradable polymkeric substance, and it can stablize the longer time.
The abbreviation that the present invention is used
VP=vinyl pyrrolidone or 1-vinylpyrrolidin-2-one
The NIPAM=N-NSC 11448
The ester of MPEG=maleic anhydride and polyoxyethylene glycol
MBA=N, N '-methylene-bisacrylamide
The TMED=Tetramethyl Ethylene Diamine
The APS=ammonium persulphate
The LCST=lower critical solution temperature
The DSC=dsc
The TGA=thermogravimetric analysis
The CMC=micelle-forming concentration
Description of drawings
Fig. 1: polymkeric substance of the present invention 1The H-NMR spectrum.
Fig. 2: polymkeric substance of the present invention 13The C-NMR spectrum.
Fig. 3: the Fourier transform infrared of polymkeric substance of the present invention (FT-IR) spectrum.
Fig. 4: the TGA thermography of polymkeric substance of the present invention.
Fig. 5: the DSC thermography of polymkeric substance of the present invention.
Fig. 6: the present invention [ 14C] the blood substance kinetic curve of polymkeric substance of mark.
Fig. 7: the subcutaneous administration 10% dextrose solution painted rabbit ear lappet of S&E position photo (contrast) after 48 hours.
Fig. 8: subcutaneous administration aqueous solutions of polymers of the present invention is the painted rabbit ear lappet of S&E position photo after 48 hours.
Fig. 9: the intravenous administration 10% dextrose solution painted rabbit ear edge of S&E vein position photo (contrast) after 24 hours.
Figure 10: intravenous administration aqueous solutions of polymers of the present invention is the painted rabbit ear edge of S&E vein position photo after 24 hours.
Figure 11: the diagram that is used to prepare and uses the typical method of nanoparticle pharmaceutical compositions of the present invention to the patient that needs are arranged.
Summary of the invention
The inventor find that the purpose that realizes all propositions can both realize, and most of limitation of prior art (if not all limitation) has obtained also overcoming through great efforts.
At first, the inventor finds to be contained simultaneously the polymkeric substance of NIPAM and VP monomeric unit, and the amount of each single monomer impurity is lower than the toxic limit of defined in the polymkeric substance that wherein obtains thus.
Particularly, the inventor finds to obtain containing NIPAM, VP and the MPEG polymkeric substance as monomeric unit, and it is substantially devoid of deleterious NIPAM and VP monomer impurity.Particularly, the inventor finds can high purity to obtain the polymkeric substance that so said NIPAM and VP foreign matter content are far smaller than the 0.001%w/w level.
Can obtain having the polymkeric substance of desired characteristic through high selective method, it comprises the aqueous solution that contains the polymkeric substance that obtains through polymerization NIPAM, VP and MPEG is carried out diafiltration or ultrafiltration step, and these are different with the method for the dialysis of being instructed in the prior art.
The polymkeric substance that obtains through the inventive method is superior to the method (US6 especially through prior art; 322; The disclosed method that comprises the step of dialysing in 817) resulting polymkeric substance, this can obtain best appreciated (like what concluded in the Table II) through contained residual monomer in the polymkeric substance more separately.
Table II: according to US 6,322, contained monomer impurity and utilize the comparison of monomer impurity contained in the polymkeric substance that diafiltration obtains according to the present invention in the polymkeric substance that the method for disclosed utilization dialysis obtains in 817
Parameter According to US 6,322, the polymkeric substance that 817 method obtains The polymkeric substance that obtains according to the inventive method
Residual NIPAM 0.066-0.076％w/w (660-760ppm) ＜0.001％w/w(＜10ppm)
Residual VP 0.008-0.011％w/w (80-110ppm) ＜0.001％w/w(＜10ppm)
Should be pointed out that dialysis relates in solution to see through semi-permeable membranes through the selectivity diffusion and makes than small molecules from than the macromole or make dissolved substances slow isolating method from colloidal solid.In typical dialysis method, the polymers soln that is used for purifying is accommodated in the semi-permeable membranes, and removes low-molecular-weight solute (monomer) through outside film, placing neat solvent (normally water).Periodically or continuously change this solvent can spread solute (monomer such as NIPAM and VP) in the solution that contains polymkeric substance concentration reduction.
Different with dialysis method, the diafiltration technology relate to fluid through pump stride the film mechanical flow, tangentially fluid is pumped (from this reason, diafiltration also is called as grossflow filtration) thus along the film surface.Institute's applied pressure makes a part of fluid optionally be diffused into the filtrate side through film.The component of polymer that is kept is not in the semi-permeable membranes cumulative.
On the other hand; Keep equating with the original bulk or the volume of the aqueous solutions of polymers of the purifying that is selected to wherein/identical or when finishing or accomplishing said operation diluted dialysis method compare; In percolation process; Because aqueous solutions of polymers tangentially flows and is pulled away, cause concentrating of the said solution that contains polymkeric substance simultaneously, obtain denseer polymers soln.For example; Contain in 5.0 premium on currency when for example the solution of 100 gram polymkeric substance is dialysed with diafiltration respectively;, preceding a kind of method obtains containing in 4.5 to 5.5 premium on currency solution of 100 gram polymkeric substance when finishing; And in the back when a kind of method finishes, the reduction of original volume or concentrate 1/4th the amounts that obtain original volume usually to sixth (1/4～1/6), and when finishing, obtain containing in about 0.8～1.3 premium on currency the solution of 100 gram polymkeric substance.
In addition, as stated, in dialysis method, being retained in solvent outside the film that accommodates polymers soln needs periodically artificial or changes continuously, and in percolation process, without any need for periodically or change the manual operation of solvent continuously.This makes the former need labor management for a long time in its operating period, and then a kind of method then is full automatic and full regulation and control, so its convenience simple to operation, does not need labor management.
In addition; Because the percolation process that can in closed environment, operate is compared with the dialysis method of in open environment, operating; Any possibility of microbial contamination all is minimum or non-existent in preceding a kind of method; Therefore will meet the requirement of operation under the aseptic condition, this not only meets GMP, and meets worldwide rules guide.
And, owing to not only comprise manual operation but also relate to the intrinsic principle of dialysis method work, so the time cycle of unit operation is long, needs are about 24～36 hours usually.By comparison, according to the intrinsic principle of its work, percolation process needs very short time cycle and its to accomplish usually need be less than 1 hour.In other words, percolation process is than dialysis method fast at least 25 times and therefore more suitable in industry.
And the time cycle that dialysis method needs quite long being used to operate and accomplish, another inherent defect of said method is that it only allows the polymers soln of purifying small volume/amount.Such limitation does not exist for percolation process, and generally speaking it allows bigger volume/amount, the for example solution to be purified of at least 4～5 times of amounts.For example, if dialysis method has the ability of purifying solution of 100 gram polymkeric substance in 5.0 premium on currency in one-period, then can in one-period, restrain polymkeric substance by 400～500 in purifying 20.0～25.0 premium on currency through percolation process.Need not go into the details; The larger process ability of percolation process be its provide except aforementioned other another one advantage advantage, said other advantage promptly: faster running time, robotization and control manipulation, convenient simple and direct, concentrate simultaneously or reduce the initial soln volume, meet GMP and rules guide, minimum or do not have microbial contamination etc.
Yet; As preceding mentioned and discussion; The purity of the polymkeric substance that the most important advantage that percolation process is superior to dialysis method is to obtain through method separately, wherein percolation process produces and is substantially free of monomer impurity and therefore nontoxic and safe polymkeric substance [referring to table-II] concerning humans consumption.
Last but be not least important; The intrinsic advantage of the another one of percolation process is if desired/must polymkeric substance be come out from solution with isolated in solid form through evaporating solvent; For example through freeze-drying; Cause the reduction of polymers soln original volume through said method so or concentrate, to about 1/4th amounts to sixth (1/4～1/6) of original volume, said evaporation/freeze dried time cycle also will significantly reduce usually.In dialysis method, owing to the reduction that does not have original volume or concentrated, if desired/and polymkeric substance is come out with isolated in solid form from solution, then said evaporation/freeze dried time cycle is with much longer.
In brief, compare with dialysis method, percolation process can easily amplify and is used for scale operation, meets GMP and therefore more feasible and friendly in industry.
The essential distinction of percolation process and dialysis method is summarised among table-III, is used for quick reference.
Though diafiltration or ultra-filtration technique are applicable to multiple purifying to a certain extent, yet its application in polymer arts is not in the news up to now and has constituted aspect novelty of the present invention and creationary one.
In addition, the inventor also through multiple spectrographic technique for example 1H-NMR, 13C-NMR and Fourier transform infrared spectroscopy (FT-IR) have characterized obtain thus highly purified and have been substantially free of the polymkeric substance of monomer impurity, and find that it has the structure (I) shown in following:
And; Research based on the radiolabeled polymkeric substance that utilizes male Swiss albino mouse to carry out; The detailed content [reference table-VI and VII and Fig. 6] that provides according to this specification sheets aft section; To draw a conclusion being conspicuous: find that polymkeric substance right and wrong of the present invention are biodegradable and in body, eliminate and not deposition and degraded vital organ rapidly that this points out said polymkeric substance to use for humans is safe and useful.
Table-III: the dialysis method of purifying aqueous solutions of polymers of the present invention and the comparison of percolation process
Parameter Dialysis method Percolation process
Batch weight Therefore limited and become restriction (for example 100 restraining polymkeric substance in 5.0 premium on currency) Can handle at least 4 to 5 times of volume/amounts (for example 400 to 500 gram polymkeric substance are in 20.0 to 25.0 premium on currency)
Treatment condition Open environment Closed environment
Treatment time Long (24 to 36 hours) Lack (＜1 hour)
Operation and convenience Artificial; Tediously long; Inconvenient Automatic and adjustable; More not tediously long; Very convenient
Microbial contamination Possibility is high Minimum or do not exist
The minimizing of solution original volume/concentrate Do not have About 1/4th to sixth (1/4 to 1/6)
The freeze-drying time cycle of solution Long (treating the 90-110% of freeze-drying original volume) Lack (being merely the 15-25% that treats the freeze-drying original volume)
Monomer impurity Very high Be lower than pharmacopeia and toxic limit
Extensibility and commercial viability Difficulty; Feasibility is less Easy expansion; Meet GMP; Very feasible
In addition; Based on toxicity research such as local toxicity (subcutaneous and intravenously), target organ dosage toxicity height widely to 800mg/kg the weight of animals, 6 months clinical dosage toxicity etc.; The detailed content [with reference to Fig. 7 to 10] that provides according to this specification sheets aft section is to draw a conclusion being for example conspicuous: find that polymkeric substance of the present invention is nontoxic, biocompatible and is safety biologically being used to prepare when being intended to be used for pharmaceutical composition that humans uses and use.
Also find polymkeric substance of the present invention (its for highly purified be substantially free of monomer impurity and be biocompatible, non-biodegradable, safe and nontoxic) especially can be used for preparing the said polymkeric substance that comprises form of nanoparticles and the pharmaceutical composition of pharmaceutically acceptable vehicle, still safety and less toxic for said pharmaceutical composition is used and/or used for humans.
Especially; Find that biocompatible, non-biodegradable, safe and nontoxic polymkeric substance of the present invention is embedded in the medicine or the compound of multiple poorly water-soluble in its polymer shell fully or almost completely; The medicine of wherein said poorly water-soluble or compound can form of nanoparticles use, and particle size is 30～150nm.
Figure S2006800519727D00141
The structure of polymkeric substance of the present invention
Particularly, find that polymkeric substance of the present invention can be used for preparing the pharmaceutical composition of form of nanoparticles, said polymkeric substance is embedded in its polymer shell with the medicine or the compound of pharmaceutically acceptable vehicle with multiple poorly water-soluble fully or almost completely.The medicine of such poorly water-soluble or compound are water-soluble less than 10mg/ml those.The medicine of these poorly water-solubles or examples for compounds include but not limited to carcinostatic agent, anti-inflammatory agent, anti-mycotic agent, antiemetic, antihypertensive drug, sexual hormoue, steroid, microbiotic, immunomodulator, narcotic etc.Can be embedded in the Taxane derivative that representative instance is a taxol, docetaxel is relevant with other of the carcinostatic agent in the said polymer shell; Irinotecan, the camptothecin derivative that TPT is relevant with other; Zorubicin, daunorubicin and relevant anthracycline derivatives; Cis-platinum; Oxaliplatin; 5 FU 5 fluorouracil; MTC; Methotrexate; VP; Betulinic ncid and verivate thereof; And Wedelolactone and verivate thereof.The representative instance that can be embedded in the anti-inflammatory agent in the said polymer shell comprises indomethacin, Ibuprofen BP/EP, KP, FLURBIPROFEN USP24, piroxicam, tenoxicam and Naproxen Base.The representative instance that can be embedded in the anti-mycotic agent in the said polymer shell comprises KETOKONAZOL and amphotericin B.The representative instance that can be embedded in the sexual hormoue in the said polymer shell comprises testosterone, oestrogenic hormon, Progesterone and Theelin,dihydro-.The representative instance that can be embedded in the steroid in the said polymer shell comprises DEXAMETHASONE BP98, prednisolone and triamcinolone.The representative instance that can be embedded in the hypotensive agent in the said polymer shell comprises captopril, ramipril, terazosin, minoxidil and Prazosin (Parazosin).The representative instance that can be embedded in the antiemetic in the said polymer shell comprises ondansetron and granisetron.The antibiotic representative instance that can be embedded in the said polymer shell comprises metronidazole and fusidic acid.The representative instance that can be embedded in the immunomodulator in the said polymer shell comprises ciclosporin and xenyl dimethyl-dicarboxylicacid.The narcotic representative instance that can be embedded in the said polymer shell comprises Propofol (Propofol), alfaxalone and Hexobarbital.
Especially for carcinostatic agent; Find that polymkeric substance of the present invention can be embedded in the medicine or the compound of poorly water-soluble in its polymer shell fully; For example taxol, docetaxel, VP and various betulinic acid derivative for example are disclosed in US 6 successively; 403,816 with we in the unsettled India application No.265/DEL/2005 that submitted on February 9th, 2005, have following structure (II), (III) and (IV) be named as those of MJ-1098, DRF-4012 and DRF-4015.
Figure S2006800519727D00151
At US 6,403, disclosed MJ-1098 (II) in 816
Figure S2006800519727D00152
Application No.265/DEL.2005 applies for No.265/DEL.2005 in India in India
In disclosed DRF-4015 (IV) among the disclosed DRF-4012 (III)
With according to people such as Burman at US 6; 365; The taxol nanoparticle pharmaceutical composition (claiming in the said patent that said pharmaceutical composition only has 12 hours stability) of disclosed method preparation compares in 191, find aforementioned poorly water-soluble medicine or compound nanoparticle pharmaceutical compositions and particularly aforementioned poorly water-soluble medicine or compound such as taxol, docetaxel, VP and imitate anticancer compound by force such as the nanoparticle pharmaceutical compositions of MJ-1098, DRF-4012 and DRF-4015 has the longer stability greater than 24 hours.Term " stability " means the time of calculating by the hour, and the medicine of wherein said poorly water-soluble or compound keep dissolved state in the pharmaceutical composition of medicine that contains this poorly water-soluble or compound, and do not produce the deposition of any medicine or compound.
In addition; In the nanoparticle pharmaceutical compositions of the medicine of aforementioned poorly water-soluble or compound and particularly the medicine of aforementioned poorly water-soluble or compound such as taxol, docetaxel, VP and imitate anticancer compound by force such as the nanoparticle pharmaceutical compositions of MJ-1098, DRF-4012 and DRF-4015 in, find in addition after 24 hours said medicine or compound be embedded in degree in the polymer micelle greater than 95%.Comparatively speaking, according to people such as Burman at US6, in 365,191 in the taxol nanoparticle pharmaceutical composition of disclosed method preparation, find even said pharmaceutical pack is embedded in the polymer micelle after 24 hours degree is merely 90%.
To contain the present invention highly purified and be substantially free of monomer impurity polymkeric substance form of nanoparticles poorly water-soluble medicine or compound pharmaceutical composition with by US 6; 365; Disclosed in 191 also is that the taxol drug compsn of form of nanoparticles compares, and the result is conspicuous in Table IV.
Table IV: the comparison of disclosed pharmaceutical composition among the medicine of poorly water-soluble of the present invention or the pharmaceutical composition of compound and the US 6,365,191
Sequence number Detailed content US6, disclosed content in 365,191 The present invention
1 The medicine of mentioned poorly water-soluble or compound Derivative of taxane, especially taxol Multiple medicine and compound
2 Used polymkeric substance in the pharmaceutical composition Contain NIPAM, VP and MPEG monomeric unit Contain NIPAM, VP and MPEG monomeric unit
3 The monomer impurity that exists in the polymkeric substance NIPAM：0.066-0.076％ w/w VP：0.008-0.011％w/w NIPAM：＜0.001％w/w VP：＜0.001％w/w
4 The size of nano particle in the pharmaceutical composition Unspecified 30-150nm
4 Stability About 12 hours ＞24 hours
5 24 hours interior entrapment efficiencies of post polymerization thing micella 90％ ＞95％
Except obtain according to the inventive method highly purified and be substantially free of the polymkeric substance of monomer impurity and contain polymkeric substance of the present invention poorly water-soluble medicine or compound pharmaceutical composition had with respect to as the advantage of preceding prior art polymers that details and pharmaceutical composition; The inventor has also found to be used to prepare the medicine of poorly water-soluble or the pharmaceutical composition high selective method of compound; The medicine of wherein said poorly water-soluble or compound are embedded in the polymer shell of polymkeric substance, and wherein used polymkeric substance prepares with form of nanoparticles of the same size.This high selective method constitutes another creative aspect of the present invention.
At first; Should be understood that; From people such as Burman at US 6; The description of embodiment 1 to 40 and the description that under title " preferred composition " and " preparation that is used for infusion ", provides in 365,191 obviously can prepare the taxol drug compsn through following steps: at first with the polymer dissolution of requirement in the diluted fluid (being generally 5% or 10% dextrose solution) of requirement; Add AS subsequently to obtain settled solution, randomly utilize buffer reagent to regulate the pH of said solution.The alcoholic solution that in the polymkeric substance of gained and the settled solution of AS in diluted fluid, adds taxol then is 0.1～10mg/ml to obtain drug level, and it is asked to protect the pharmaceutical composition for the form of nanoparticles that is used to use in essence.
As previously mentioned; Though US 6,365, the size of the 191 not mentioned nano particles that obtain thus; Yet find to attempt according to people such as Burman at US 6 the inventor; When method described in 365,191 the embodiment 1 to 40 and the method that under title " preferred composition " and " preparation that is used for infusion ", provides prepare the taxol drug compsn, produced or caused the nano particle that causes not of uniform size.
To this background technology, the inventor find the preparation of nano particle of the same size be highly selective and depend primarily on:
I) speed of adding taxol alcoholic solution in polymkeric substance and the solution of other vehicle in diluted fluid;
The ii) volume of taxol alcoholic solution and to the volume of the diluted fluid that wherein adds said taxol alcoholic solution;
Iii) the taxol alcoholic solution is joined the internal diameter or the pore size (bore size) of used syringe needle in polymkeric substance and the solution of pharmaceutically acceptable vehicle in diluted fluid; With
Iv) when adding the taxol alcoholic solution, accommodate the position of the container of said diluted fluid and polymkeric substance and pharmaceutically acceptable vehicle.
Particularly, the inventor finds only can realize through following method the preparation of the nano particle that size of particles consistent (having minimum or insignificant size variation) is consistent with the interior drug load of polymer shell:
A) in specific time, in polymkeric substance and the solution of other vehicle in diluted fluid, add the taxol alcoholic solution through syringe;
B) utilize the syringe needle of internal diameter 0.305mm～0.356mm in polymkeric substance and the solution of pharmaceutically acceptable vehicle in diluted fluid, to add the taxol alcoholic solution of smaller size smaller; Or
C) utilize the syringe needle of internal diameter 0.559～0.711mm in polymkeric substance and the solution of pharmaceutically acceptable vehicle in diluted fluid, to add the taxol alcoholic solution of comparatively large vol;
D) injection taxol alcoholic solution in polymkeric substance and the solution of other vehicle in diluted fluid, the syringe needle that wherein adds the used syringe of taxol alcoholic solution should keep immersing in the said diluted fluid solution; With
E) randomly, in polymkeric substance and the solution of other vehicle in diluted fluid, make the container that accommodates said diluted fluid keep inverted position during the injection taxol alcoholic solution.In addition, find only to pass through said process for selective, can realize the longer stability of pharmaceutical composition.
Find that also above-mentioned high selective method is not only to be confined to prepare taxol nanoparticle; And effectively same in the consistent nano particle of the size of particles of medicine or the compound of other poorly water-soluble of preparation, especially mentioned docetaxel, VP, the betulinic ncid in front, imitate anticancer betulinic acid derivative suc as formula the MJ-1098 of (II), the DRF-4012 of formula (III), the DRF-4015 of formula (IV) by force.
Especially find; Promptly time of joining in the solution in diluted fluid of polymkeric substance and other vehicle (volume injected about 35 times) of medicine or the compound solution of 1 to 5ml poorly water-soluble surpassed for 4 seconds if with smaller size smaller; If perhaps the internal diameter of syringe needle (medicine of injection poorly water-soluble or the solution of compound are used) is outside the scope of 0.305mm～0.356mm; Then such adding cause producing the inconsistent poorly water-soluble of size of particles medicine or compound nano particle and cause the pharmaceutical composition poor stability, mean that thus said solution can not keep clarification in a long time and will become oyster white within a short period of time.
Similarly; Especially find; Promptly time of joining in the solution in diluted fluid of polymkeric substance and other vehicle (volume injected about 35 times) of medicine or the compound solution of the poorly water-soluble of 5～15ml surpassed for 10 seconds if with comparatively large vol; If or the internal diameter of syringe needle (medicine or the compound solution of injection poorly water-soluble are used) is outside 0.559～0.711mm scope; Then such adding cause producing the inconsistent poorly water-soluble of size of particles medicine or compound nano particle and cause the pharmaceutical composition poor stability, mean that thus said solution can not keep clarification in a long time and and will become oyster white within a short period of time.
The cancer therapy drug or the compound that can illustrate about two kinds of poorly water-solubles are the pharmaceutical composition of the DRF-4012 of taxol and betulinic acid derivative formula (III), joining day of wherein said medicament solution and the influence that such solution joins in polymkeric substance and the solution of pharmaceutically acceptable vehicle in diluted fluid footpath within the used syringe needle is summarised among table-V.
Pharmaceutical composition of the present invention provides with following two bottle medicine boxs expediently:
A) one bottle of medicine that contains poorly water-soluble or compound with the proper concn of said medicine in water-miscible solvent or the solution in its mixture; With
B) another bottle contains of the present invention highly purifiedly and be substantially free of the polymkeric substance and the solution of pharmaceutically acceptable vehicle in water-containing solvent (the normally water of injection stage) of monomer impurity, and these two bottles all are aseptic and under aseptic condition, produce and load.
Using to the content of said two bottles being joined in the said diluted fluid before the humans then.
Randomly, said medicine box also can comprise the syringe needle that diluted fluid and syringe and internal diameter are 0.305～0.356mm (if with small volume for example a) the content of 1～5ml bottle to join be the about 35 times bottle b of its volume) in the content) or diluted fluid and syringe and internal diameter be 0.559～0.711mm syringe needle (if with comparatively large vol as the bottle of 10～15ml a) content to join be the about 35 times bottle b of its volume) in the content).
Particularly under the medicine box that contains taxol is used to use to the situation of patient with the treatment breast cancer, said two bottle medicine boxs will contain:
A) one bottle, contain the solution of 400mg taxol in 20ml ethanol;
B) another bottle, contain 200mg highly purified and the polymkeric substance and the pharmaceutically acceptable vehicle that are substantially free of monomer impurity of the present invention in 20ml water solution and
Randomly; Said medicine box also can comprise 10% dextrose solution of one bottle of 500ml; With being used for of syringe and internal diameter 0.711mm with the syringe needle of bottle injection of solution a) to the bottle of said 500ml 10% dextrose solution; In this has been no more than time period of 10 seconds, preferably be no more than in time period of 6 seconds in the bottle of said 500ml 10% dextrose solution, added bottle b) solution, in consistent (the having minimum or insignificant size variation) of the size of particles that is suitable for using with preparation and the polymer shell drug load consistent and have stable nanoparticle pharmaceutical compositions of length.
Table-V: the medicine of poorly water-soluble or the joining day of compound solution and such solution joined the influence in footpath within the used syringe needle in polymkeric substance and the solution of other vehicle in diluted fluid
Figure S2006800519727D00201
In a word, as previously mentioned, the present invention is a progress aspect the circumscribed method of great majority (if not all) that solves art methods in the nano particle technical field is provided, and provides:
I) highly purified and be substantially free of the polymkeric substance that is selected from NIPAM, VP and three kinds of monomeric units of MPEG comprising of monomer impurity, level＜0.001% of wherein said polymkeric substance toxic NIPAM and VP; And, confirmed that it is used for humans is biocompatible, non-biodegradable, safe and nontoxic;
Ii) be used to prepare highly purified and be substantially free of the high selective method of the polymkeric substance (level＜0.001% of wherein said polymkeric substance toxic NIPAM and VP) that containing of monomer impurity be selected from NIPAM, VP and three kinds of monomeric units of MPEG, it comprises that the aqueous solutions of polymers with preparation thus carries out diafiltration;
The iii) pharmaceutical composition of the medicine of the poorly water-soluble of form of nanoparticles or compound; It comprises highly purified and is substantially free of the polymkeric substance and the pharmaceutically acceptable vehicle of monomer impurity, and therefore said pharmaceutical composition safety non-toxic also is very suitable for humans and uses or use;
Iv) be used to prepare the high selective method of pharmaceutical composition of medicine or compound of the poorly water-soluble of form of nanoparticles; Said pharmaceutical composition comprises highly purified and is substantially free of the polymkeric substance and the pharmaceutically acceptable vehicle of monomer impurity, and said pharmaceutical composition has consistent nano particle size of particles and consistent drug load; With
The v) pharmaceutical composition of the medicine of the poorly water-soluble of form of nanoparticles or compound; It comprises highly purified and is substantially free of the polymkeric substance and the pharmaceutically acceptable vehicle of monomer impurity, and said pharmaceutical composition has consistent nano particle size of particles and higher drug load and long stability.
Embodiment
A. the preparation of polymkeric substance of the present invention
Polymkeric substance of the present invention comprises three kinds of monomeric units that are selected from NIPAM, VP and MPEG, and wherein polymer chain is mutually crosslinked through the linking agent that does not contain any sulfydryl or disulfide linkage.
No matter when use, said linking agent is through cross-link bond being provided in the simple linear polymer chain and between polymerization period, play important effect, and its bifunctional ethenyl derivatives normally.It also can have more than two functional groups, and promptly it can have plural reaction site.The bifunctional ethenyl derivatives that can advantageously use is N, N '-methylene-bisacrylamide (MBA), and it is preferred.
Can prepare polymkeric substance of the present invention through the general method that polyreaction adopts usually.
In a specific embodiments, can be in the presence of acvator, polymerization starter and linking agent in aqueous medium, polyoxyethylene glycol (molecular weight 6000) ester (MPEG) of monomer N-NSC 11448 (NIPAM), l-vinyl-2-pyrrolidone (VP) and maleic anhydride be carried out the incompatible preparation of radical polymerization polymkeric substance of the present invention.
Weight ratio that can 55: 22～65: 35 is used the combination of monomer N-NSC 11448 (NIPAM) and vinyl pyrrolidone (VP), and available comonomer composition (NIPAM+VP): MPEG is 80: 20～95: 5.More specifically and more preferably; Weight ratio that can 58: 32～62: 28 is used the combination of monomer N-NSC 11448 (NIPAM) and vinyl pyrrolidone (VP); (NIPAM+VP) with 90: 10～95: 5: MPEG uses comonomer composite; Find it and give the desired biocompatibility of polymkeric substance, non-biodegradable and biological safe characteristic; Because this concrete ratio always causes forming high at random ramose NIPAM and VP copolymer unit, its outer shell by the hydrogen bond formation of diester adducts (main) through maleic anhydride-polyoxyethylene glycol (MPEG) and monoesters adducts (accessory) is stablized.
Polymerization starter plays important effect in the initiation radical forms.Spendable initiator can be a peroxide cpd; For example diacyl peroxide, Lucidol, diacetyl peroxide, dialkyl peroxide, tert-butyl peroxide and t-amyl peroxy thing or based on the polymerization starter of nitrile for example 2; 2 '-Diisopropyl azodicarboxylate (AIBN) or based on polymerization starter such as the ammonium peroxydisulfate (Ammonium perdisulphate) or the ammonium persulphate (APS) of inorganic salt, it uses or make up use separately.
In the above-mentioned polymerization starter, ammonium persulphate (APS) is preferably a kind of.
Though the polymerization starter initiated polymerization, yet, find that polyreaction is activated agent and quickens, said acvator catalysis forms radical by polymerization starter.Such acvator can be selected from Tetramethyl Ethylene Diamine (TMED) and ferrous ammonium sulphate (FAS), and wherein the combination of TMED and FAS is preferred.Any combination of polymerization starter and acvator can be used for polyreaction.Also can use two or more initiators.Equally, also can use two or more acvators.
As previously mentioned, no matter when use, said linking agent is through cross-link bond being provided in the simple linear polymer chain and between polymerization period, play important effect, and bifunctional ethenyl derivatives normally.It can have more than two functional groups, and promptly it can have plural reaction site.The bifunctional ethenyl derivatives that can advantageously use is N, N '-methylene-bisacrylamide (MBA), and it is preferred.
In the presence of rare gas element (can be nitrogen or argon gas), carry out polymerization.
Generally speaking, be that polyoxyethylene glycol (molecular weight 6000) ester (MPEG) of N-NSC 11448 (NIPAM), 1-vinyl 2-Pyrrolidone (VP) and maleic anhydride is dissolved in the aqueous solvent (normally water) and carries out polyreaction at first with each monomer of appropriate amount.In each monomeric aqueous solution of gained thus, add linking agent and acvator in succession.Made the solution degassing in about 30～60 minutes through the bubbling rare gas element.In the solution of the degassing, add the polymerization starter aqueous solution and said solution under 25 ℃～45 ℃ temperature, preferably under 25 ℃ to 35 ℃ temperature, continuous bubbling rare gas element for some time accomplishes and carries out polymerization up to polymerization.
The amount of 1.3～1.5%w/w that can total monomer content is used linking agent, and more preferably uses with 1.35～1.4%w/w of total monomer content.
The amount of 15～18%w/w that can total monomer content is used acvator, and more preferably uses with 15～16%w/w of total monomer content.
The amount of 20～30%w/w that can total monomer content is used polymerization starter, and more preferably uses with 23～25%w/w of total monomer content.
Through HPLC monitoring polyreaction process, in about 3～6 hours, accomplish usually.
After polyreaction is accomplished, through the disposable 0.2 μ m poly (ether sulfone) film 1 of sterilizing in advance " bag type filter (0.8 and 0.2 μ m aperture, DPS-5101AA-201 type) (manufacturers: M/sAdvanced Microdevices Pvt.Ltd, India) filtering solution.Utilize Proflux M12 (Millipore) diafiltration equipment that the filtering content in the reaction vessel is carried out diafiltration to remove monomer impurity and other low molecular weight impurities.
Usually in less than 1 hour, accomplish diafiltration and not only produce the solution that is substantially free of monomer impurity usually but also the solution that produces conc forms (be generally the solution original volume that carries out diafiltration 1/4th to sixth (1/4～1/6)).If desired, the enriching soln that is substantially free of monomer impurity of gained can carry out another filtration cycle thus.Can be with the present invention highly purified and polymkeric substance enriching soln that be substantially free of monomer impurity carry out step of freeze drying and be used for using or can directly using such enriching soln to be used to prepare described pharmaceutical composition at pharmaceutical composition with the polymkeric substance that obtains the solid lyophilized form.
In typical embodiment, through being that polyoxyethylene glycol (molecular weight 6000) ester (MPEG) of N-NSC 11448 (NIPAM), l-vinyl-2-pyrrolidone (VP) and maleic anhydride is dissolved in and carries out polyreaction in the water with each an amount of monomer.The linking agent that in each the monomeric aqueous solution that obtains thus, adds proper volume is N; The aqueous solution (about 5%w/v) of N '-methylene-bisacrylamide (about 1.37%w/w of total monomer content) and acvator combination; Said acvator contains the Tetramethyl Ethylene Diamine (TMED, about 15.4%w/w of total monomer content) of proper volume and the aqueous solution (0.5%w/v) of ferrous ammonium sulphate (about 0.1%w/w of total monomer content).Preferred elder generation adds a kind of acvator and adds other a kind of acvator and polymerization starter afterwards.Made the solution degassing in about 30 minutes through bubbling nitrogen.In the solution of the degassing, add the polymerization starter of proper volume, the aqueous solution (about 80%w/v) of ammonium persulphate (about 24%w/w of total monomer content), preferably under 25 ℃～35 ℃ temperature, under continuous bubbling nitrogen for some time, make said solution carry out polymerization to accomplish up to polymerization.Common said polyreaction was accomplished in 3～5 hours.
After polyreaction is accomplished, through the disposable 0.2 μ m poly (ether sulfone) film 1 of sterilizing in advance " bag type filter (0.8+0.2 μ m aperture) filtering solution.Filtering content in the reaction vessel is carried out diafiltration to remove monomer impurity and other low molecular weight impurities.
In typical embodiment; Can for example be that the solution of polymkeric substance in water of 1 gram/50ml carries out diafiltration with concentration; Therefore; Obtain polymkeric substance after the diafiltration at about 1/4th enriching solns (for example 1 gram polymkeric substance is in about 12～13ml water) to the original volume of sixth (1/4～1/6), it comprises less than the NIPAM of 0.001%w/w and VP.
Through the residual monomer in HPLC detection and the quantifying polymers, especially residual VP and NIPAM.Can be used for detecting monomeric HPLC system and utilize Agilent 1100 series or the equivalent of anti-phase RP-18 (C-18) post [Lichrospher RP-18e, 5 μ, 250mm * 4mm].Used moving phase is the mixture of 80: 20 ratios of water and acetonitrile, and flow velocity is 1ml/ minute, and sampling volume is 50 μ l.
Be 10 minutes working time, and column temperature is 30 ℃, and detecting wavelength is 226nm.
Under these conditions, the RT of NIPAM is about 3 minutes, and the RT of VP is about 5 minutes.
The polymkeric substance enriching soln that so obtains is highly purified and is substantially free of monomer impurity, can it be carried out step of freeze drying and be used for using or can directly using such enriching soln to be used to prepare said pharmaceutical composition at pharmaceutical composition with the polymkeric substance that obtains the solid lyophilized form.Yet, preferably use such polymkeric substance enriching soln to be used for the compounding pharmaceutical compsn.
B. the sign of polymkeric substance of the present invention
To carry out spectroscopic analysis widely for example through the polymkeric substance of the present invention that this paper aforesaid method obtains 1H-NMR, 13C-NMR, Fourier transform infrared spectroscopy (FT-IR) and heat are analyzed for example dsc (DSC) and thermogravimetric analysis (TGA) etc. to illustrate the structure of resulting polymers thus.
Polymkeric substance of the present invention is at CDCl 3In 1The H-NMR spectrum has shown the peak that following δ (ppm) locates: 1.14 (broad peak ,-CH (CH 3) 2); 1.45 (broad peak ,-CH 2-CH-N (VP-ring); 1.63 (broad peak ,-CH 2-CHC (=O) NH); 1.99 (broad peak ,-CHC (=O) NH-), CH 2(VP ring), 2.36 (CH 2, the VP ring), 3.0 (O-CH 2-CH 2-), 3.23 (CH 2-N-); 3.62-3.66 (broad peak, CH 2, MPEG); 3.72 (NH-CH (CH 3) 2); 3.97 (broad peak, CH).Polymkeric substance of the present invention 1The H-NMR spectrum is summarised among Fig. 1.
Polymkeric substance of the present invention 13The C-NMR spectrum has shown the peak that following δ (ppm) locates: 174 (C=O); 76.6-77.6 (CDCl 3Multiplet with CH on the main polymer chain); 70.6 (the CH of MPEG 2), 41.6 (the unitary CH of sec.-propyl), the 31.8 (CH of main polymer chain 2), the 22.6 (CH of sec.-propyl 3).Polymkeric substance of the present invention 13The C-NMR spectrum is summarised among Fig. 2.
The Fourier transform infrared of polymkeric substance of the present invention (FT-IR) spectrum has shown at following frequency values (cm -1) peak located: 3500 (s, OH); 3296 (s, NH, secondary amide); 2972-2933 (s, CH, CH 2, CH 3); 1651 (broad peak, strong, split the peak, the C=O of ester C=O and acid amides I); 1546 (s, the C=O of the NH flexural vibration of acid amides II and possible free acid, weak); 1387,1367 (sec.-propyl bimodal, CH 3, distortion), and 1172-1129 (m, O-C-O).The Fourier transform infrared of polymkeric substance of the present invention (FT-IR) spectrum is summarised among Fig. 3.
These characterization researchs confirm that polymkeric substance of the present invention has the described structure as shown in the formula (I):
In addition, in order to characterize in detail the physicochemical property of said polymkeric substance, estimated multiple character such as thermal properties, micelle-forming concentration (CMC), solubleness and pH, the stability in storage of polymkeric substance.
Thermogravimetric analysis (TGA) shows from 51 ℃ to 260 ℃ and has some weight loss, and this shows solvent loss and some macromolecular reactions, and said macromolecular reaction maybe be especially appears in the polymkeric substance MPEG unit beginning degraded (in about 310 ℃ of appearance) before.This shows that polymkeric substance has high thermostability, and said thermostability possibly provided by the MPEG unit to a great extent.The TGA thermography of polymkeric substance of the present invention is summarised among Fig. 4.
In addition, differential scanning calorimetric (DSC) curve of the polymkeric substance of Fig. 5 representative does not show any second-order transition temperature (Tg), and only observes 58 ℃ temperature of fusion (Tm) and 38.4 ℃ recrystallize point temperature (Tc).Lacking any clearly Tg maybe the high branched structure of indicated altitude inflexible, also maybe be also owing to the hydrogen bond widely that forms with MPEG.
Figure S2006800519727D00261
The structure of polymkeric substance of the present invention
The lower critical solution temperature of polymkeric substance (LCST) value is in 50～60 ℃ of zones.In addition, this also is the important parameter of amphiphilic polymers at aqueous phase, is illustrated in to be under certain so-called LCST temperature during thermal response changes mutually.Be lower than LCST, polymkeric substance will show the chain configuration of soluble stretching, extension, i.e. wetting ability behavior.Be higher than LCST, polymkeric substance changes to comply with the insoluble hydrophobicity aggregate of formation mutually.This character can be used for detecting the ability that in appropriate solvent, forms the micellar ability and in pharmaceutical application, in drug delivery system, show.
Micelle-forming concentration (CMC) is definition nano-carrier embedding ability and another important parameter of confirming stability.This is that amphiphilic polymers or individual (unimer) form the minimum concentration that can pharmaceutical pack be embedded in the micellar structure in its hydrophobic core.The CMC value of polymkeric substance of the present invention is about 0.2mg/ml.In addition, the polymkeric substance known and protein and the hemocyte physiologically acceptable that contain thermo-sensitivity and pH sensitive monomer such as N-NSC 11448 (NIPAM) and 1-ethenyl pyrrolidone 2-ketone (VP).In addition, be that LCST, good hydrogen bond, micella and hydrogel form ability owing to gather the reversible temperature transition of (NIPAM), its biomedical applications is quite extensive.Equally, Vinylpyrrolidone polymer (being called polyvidone again) polymkeric substance also is highly water-soluble and forms hydrogen bond widely with water.It is the new system of mixing (incorporating system) of design that the purpose of this polymkeric substance is used; The predetermined monomer of varying strength mixes in the said system of mixing, cause forming thermally sensitized, pH responsive, polymer nano granules stable, that contain wetting ability and hydrophobic group is so that will be in water poorly soluble medicine dissolution.
Find very unexpectedly to have been given polymkeric substance desired biocompatibility, non-biodegradable and biological safe characteristic by stable unitary formation of being made up of NIPAM and VP of random high branched copolymers of shell coating, said shell coating is through having 80: 20 to 95: 5 (NIPAM+VP): the NIPAM of MPEG and 55: 22～65: 35: the diester adducts (main) and the monoesters adducts (accessory) of maleic anhydride-polyoxyethylene glycol (MPEG) that the comonomer of VP is formed are formed by hydrogen bond.Particularly, find consisting of 90: 10 or 95: 5 and used NIPAM as (NIPAM+VP): MPEG: the VP unit obtains better result (higher LCST, higher productive rate, higher the percentage from taxol nanoparticle release) when being 58: 32～62: 28.Used monomeric ratio also is consistent in final polymkeric substance, and by multiple research for example 1H-NMR, 13C-NMR, Fourier transform infrared (FT-IR) spectral investigation confirm.
C. the biocompatibility of polymkeric substance of the present invention and non-biodegradable
When utilize male Swiss albino mouse estimate [ 14C] during pharmacokinetics, bio distribution and the elimination of polymkeric substance of mark, radioactivity haemoconcentration curve display is for having the short transformation period T of elimination of 0.448 ± 0.157 hour (26.88 minutes) 1/2(β) with the diphasic curve (Fig. 6) of 54.7ml/ hour quick clearance rate.This result of study is summarised among table-VI and the VII.
Table-VI: the pharmacokinetic parameter of polymkeric substance of the present invention
Parameter Estimated value ± SE
T 1/2(K10) 0.152 ± 0.018 hour
T 1/2(α) 0.065 ± 0.014 hour
T 1/2(β) 0.448 ± 0.157 hour
C max 82.96±5.11μg/mL
AUC 18.29 ± 1.62 hours * μ g/ml
CL 54.67 ± 4.86ml/ hour
MRT 0.465 ± 0.13 hour
V ss 25.43±5.2ml
The leading approach of find eliminating be the urine (at 48 hours: urine was 66.91%, and ight soil is 17.39%) and the recovery data until 48 hours of gathering account for injected radioactive 84.87%.Tissue distribution can be ignored.Find that kidney, liver, skin and intestines are target organs.Yet the level of polymkeric substance in tissue removed through urine and ight soil fast.
Table-VII: the recovery of radio-labeling polymkeric substance of the present invention
Figure S2006800519727D00281
Therefore, in a word, find that said polymkeric substance fast from body elimination and not deposition and degraded vital organ, shows that it is safe and useful that said polymkeric substance uses the mankind.
D. the toxicity research of polymkeric substance of the present invention
The toxicity research that carries out formula (I) polymkeric substance is to estimate:
(i) local toxicity (subcutaneous and intravenously);
(ii) up to the target organ dosage toxicity of 800mg/kg the weight of animals; With
(iii) 6 months clinical dosage toxicity
D (i) local toxicity (subcutaneous and intravenously)
In the rabbit ear, measure polymkeric substance toxicity behind the polymkeric substance of single subcutaneous administration 100 μ l 75mg/ml; When injection detected after 48 hours; Cause mild inflammation in the injection site, show that polymkeric substance of the present invention does not cause any local toxicity in site of administration after subcutaneous administration.
In rabbit ear vein with the polymkeric substance of the present invention of continuous 5 days intravenous administration 75mg/ml of the dosage of 125mg/kg to measure the toxicity of polymkeric substance of the present invention; And obtain analog result, prove that further polymkeric substance of the present invention does not cause any local toxicity in site of administration.
The representative photo of the subcutaneous injection 10% dextrose solution painted rabbit ear lappet of S&E position after 48 hours is presented among Fig. 7, and the photo of the subcutaneous injection aqueous solutions of polymers painted rabbit ear lappet of S&E position after 48 hours is presented among Fig. 8.
The representative photo at the intravenous injection 10% dextrose solution painted rabbit ear edge of S&E vein position after 24 hours is presented among Fig. 9, and the photo at the intravenous injection aqueous solutions of polymers painted rabbit ear edge of S&E vein position after 24 hours is presented among Figure 10.
D is target organ dosage toxicity (up to the 800mg/kg the weight of animals) (ii)
In addition, in the Wistar rat special to capillary blood vessel system evaluation use to the toxicity of possible target organ and through the single intravenous push and measured toxicity.With two different dosages is that 400mg/kg and 800mg/kg use polymkeric substance.Under study condition, in rat, use polymkeric substance of the present invention and do not cause any mortality ratio or any observable toxicity sign or symptom with any dosage single intravenous push (intravenous bolus).Rat whose body weight and mean body weight all show stable increase in polymer treatment group and control group.Compare with contrast, the body weight of the animal of under two dosage, handling shows no significant difference.
In utilizing the rat of polymer treatment, hematologic parameter is in the NL in whole research.The biochemical parameters of the animal of handling with two dosage is also in NL.The photo-reactive degree is measured (Photoactometer) test and is shown that respectively the locomotor activity between the 7th day and the 21st day control group and treatment group does not have significant difference, and the prompting polymkeric substance does not have any neurotoxicity.
Treatment group shows similar histologic characteristics with the control group sample.On vital organ such as liver, the heart, lung, kidney, spleen, stomach, colon, leg muscle and eye, carry out Histological research.All research organs all show normal configuration under light microscopy.Scrutiny each organ the capillary blood vessel system and in any organ, do not find pathological characteristics.In addition, in the capillary blood vessel system of the animal of polymer treatment, do not change.
According to above observation; Clearly; Polymkeric substance of the present invention did not all cause any general toxicity or any significant histology toxicity in 5 days with 400mg/kg body weight and 800mg/kg body weight continuous administration, show polymkeric substance of the present invention be biologically safety and be avirulent.
D is 6 months clinical dosage toxicity (iii)
In addition, the polymkeric substance that in rat, is used for nanoparticle formulations through intravenous injection has been studied 6 months clinical dosage toxicity.Use male/female Wistar rats to carry out this research and once (the about 26 weeks) administration in the lateral tail vein medium sized vein in 180 days time period circularly of per three weeks.It is general movable and healthy that treatment group and control animals keep during studying.The polymer concentration of finding to be equivalent to the 10mg/kg medicine in the research is safe in animal.The minimum change of the Histological parameter that is paid close attention to is in the normal range of Wistar rat and find relevant with processing.
Above-mentioned research shows that institute's synthetic polymkeric substance is nontoxic and biologically can be used for pharmaceutical compositions safely.
E. the pharmaceutical composition that comprises polymkeric substance of the present invention
As previously mentioned; Highly purified and formula of the present invention (I) polymkeric substance that be substantially free of especially residual monomer NIPAM and VP＜0.001% of monomer impurity can be advantageously used in the pharmaceutical composition of form of nanoparticles of medicine or the compound of preparation poorly water-soluble, and said pharmaceutical composition is used humans or used is safe and nontoxic.
Particularly, polymkeric substance of the present invention can be used to prepare the pharmaceutical composition of form of nanoparticles with pharmaceutically acceptable vehicle, and the medicine or the compound of multiple poorly water-soluble is embedded in its polymer shell fully or almost completely.
In addition, as previously mentioned, medicine or the compound that can be used for the poorly water-soluble in the pharmaceutical composition of the present invention is usually water-soluble less than 10mg/ml those.
The medicine of such poorly water-soluble or examples for compounds include but not limited to carcinostatic agent, anti-inflammatory agent, anti-mycotic agent, antiemetic, hypotensive agent, sexual hormoue, steroid, microbiotic, immunomodulator, narcotic etc.Can be embedded in the Taxane derivative that representative instance is a taxol, docetaxel is relevant with other of the carcinostatic agent in the said polymer shell; Irinotecan, the camptothecin derivative that TPT is relevant with other; Zorubicin, daunorubicin and relevant anthracycline derivatives; Cis-platinum; Oxaliplatin; 5 FU 5 fluorouracil; MTC; Methotrexate; VP; Betulinic ncid and verivate thereof; And Wedelolactone and verivate thereof.The representative instance that can be embedded in the anti-inflammatory agent in the said polymer shell comprises indomethacin, Ibuprofen BP/EP, KP, FLURBIPROFEN USP24, piroxicam, tenoxicam and Naproxen Base.The representative instance that can be embedded in the anti-mycotic agent in the said polymer shell comprises KETOKONAZOL and amphotericin B.The representative instance that can be embedded in the sexual hormoue in the said polymer shell comprises testosterone, oestrogenic hormon, Progesterone and Theelin,dihydro-.The representative instance that can be embedded in the steroid in the said polymer shell comprises DEXAMETHASONE BP98, prednisolone and triamcinolone.The representative instance that can be embedded in the hypotensive agent in the said polymer shell comprises captopril, ramipril, terazosin, minoxidil and Prazosin.The representative instance that can be embedded in the antiemetic in the said polymer shell comprises ondansetron and granisetron.The antibiotic representative instance that can be embedded in the said polymer shell comprises metronidazole and fusidic acid.The representative instance that can be embedded in the immunomodulator in the said polymer shell comprises ciclosporin and xenyl dimethyl-dicarboxylicacid.The narcotic representative instance that can be embedded in the said polymer shell comprises Propofol, alfaxalone and Hexobarbital.
The medicine of poorly water-soluble or the pharmaceutical composition of compound comprise two medicine boxs manifestation with bottle (kit-vial) usually, its comprise on the one hand a medicine that accommodates poorly water-soluble with water mutual solvents or its mixture in the bottle of solution (said medicine or compound concentrations are suitable); Comprise one on the other hand and accommodate highly purified and be substantially free of the bottle of polymkeric substance of the present invention and the solution of pharmaceutically acceptable vehicle in water-containing solvent (the normally water of injection stage) of monomer impurity, two medicine boxs all are aseptic with bottle and under aseptic condition, produce and filling.Then two bottles content is added continuously to and is used in the diluted fluid using to people/animal.Should be pointed out that as previously mentioned and as mentioned below that the medicine of poorly water-soluble or compound are embedded in the polymer shell of used polymkeric substance wherein and with form of nanoparticles of the same size and prepare.Medicine or the compound that is included in two poorly water-solubles in the bottle with water mutual solvents or its mixture in solution and poorly water-soluble medicine or compound with water mutual solvents or its mixture in the volume ratio of solution be generally 1: 1～1: 10, preferred proportion is 1: 1.
Randomly; Said two medicine boxs use the manifestation of bottle also can comprise the syringe needle that diluted fluid and syringe and internal diameter are 0.305～0.356mm or 0.559～0.711mm, depend on the medicament solution volume and the diluted fluid volume that contains polymkeric substance and vehicle to the humans that needs are arranged that be used to use to be mixed.
Can be used for dissolving the medicine of poorly water-soluble or the suitable water-miscible solvent of compound comprises fatty alcohol, especially ethanol; Dialkyl amide, especially N and N,N-DIMETHYLACETAMIDE; Dialkyl sulphoxide, especially DMSO 99.8MIN. and diethyl sulfoxide; Different molecular weight polyethylene glycol; The W 166 of different molecular weight; Tensio-active agent, especially Polysorbate 80, Polysorbate 20; The vegetables oil of polyethoxylated and the Viscotrol C of polyethoxylated; Glycerine etc.
The pharmaceutically acceptable vehicle of available advantageously comprises Sodium desoxycholate; Various biliary saltss; The polysorbate of different stage, especially Polysorbate 80, Polysorbate 20, the vegetables oil of polyethoxylated and the Viscotrol C of polyethoxylated; Polysaccharide is Vadex, sucrose, lactose, N.F,USP MANNITOL etc. for example; The SPAN of different stage or spans; Different stage sell pool type (myrj); The Prist of different stage (poloxomer) etc., and the buffer reagent that is used to regulate pH.Can use any buffer reagent well known in the art to be used for the pH of regulator solution, in a preferred embodiment, using Trisodium Citrate is favourable as buffer reagent.
In pharmaceutically acceptable vehicle, Sodium desoxycholate is preferred, because it has the effect of stabilizing pharmaceutical composition, and buffer reagent is used for finding that also buffer reagent has the effect of stabilizing pharmaceutical composition in the scope with pH regulator to 6.0～8.5 of infused fluid.
Pharmaceutical composition can have poorly water-soluble medicine or compound suitable load or dosage and select the optimal load or the dosage of said medicine or compound, depend primarily on character, its solvability of said medicine or compound and use the illness that it is treated.Under the situation of pharmaceutically acceptable vehicle, the ratio or the amount that can be used in the pharmaceutical composition depend on the medicine that is included in the poorly water-soluble in the compsn or the character and the load of compound equally successively.
Can prepare the medicine of poorly water-soluble of the present invention or the nanoparticle pharmaceutical compositions of compound in the following manner:
I) preparation medicine enriched material comprises the medicine of poorly water-soluble or compound dissolution in suitable water-miscible solvent or its mixture;
Ii) prepare the concentrated liquid that contains of polymkeric substance and pharmaceutically acceptable vehicle, may further comprise the steps:
A) at first the highly purified of requirement and formula (I) polymkeric substance that is substantially free of especially toxicity NIPAM and VP level＜0.001% of monomer impurity are joined and obtain solution in the proper amount of water for injection;
B) pharmaceutically acceptable vehicle and buffer reagent are joined in the solution of polymkeric substance in water;
Iii) mixing step iib) solution in and diluted fluid and obtain settled solution;
Iv) utilizing internal diameter is the syringe needle of 0.305～0.356mm, with step I) the smaller size smaller of solution join in the step I solution ii); Perhaps
V) utilizing internal diameter is the syringe needle of 0.559～0.711mm, with step I) the comparatively large vol of solution join in the step I solution ii);
Vi) with step I) injection of solution in step I solution ii), wherein add step I) the used syringe needle of solution is immersed in the step I solution ii) keeping; With
Vii) randomly, at injecting step i) will accommodate during the solution step I ii) the container of solution remain on inverted position,
Thereby is the medicine of 30～150nm or the nano particle of compound with the medicine of poorly water-soluble or compound fully or near fully being embedded in the polymer shell and producing size of particles.Such infused fluid is keeping stable more than 24 hours, wherein to be loaded into polymer latex intrafascicular for the maintenance of the medicine 95% or more.
Should point out in this article, the selection of diluted fluid is depended primarily on used poorly water-soluble medicine or compound character and pharmaceutical composition use illness.Suitable diluted fluid can be selected from but be not limited to water, salt solution, 5% and 10% dextrose solution, Vadex and sodium-chlor solution, sodium lactate solution, Lactated Ringer'S Solution (lactated Ringer solution), mannitol solution, N.F,USP MANNITOL and Vadex or sodium-chlor solution, ringer's solution, sodium chloride solution, sterile water for injection and contain the polycomponent electrolyte solution of the various combination of ionogen, Vadex, fructose and Nulomoline.Preferably, said diluted fluid is to contain the fluid of Vadex and water and be more preferably 5% and 10% dextrose solution.
Be used for preparing nanoparticle pharmaceutical compositions of the present invention and be illustrated in Figure 11 to the preferred method that the patient that these needs are arranged uses said pharmaceutical composition.
According to following indefiniteness embodiment the present invention is described in further detail, yet, never should be with its scope that is construed as limiting the invention.
Should be pointed out that in following embodiment the diafiltration equipment that is used for purified polymer is that (manufacturers: Millipore), the dialysis machine that is used for purified polymer is cellulose membrane-D-9402 (manufacturers: Sigma) to Proflux M12 diafiltration equipment.
Experimental section
Reference embodiment-1
Utilize dialysis method to prepare polymkeric substance
In the 2L Glass Containers, carry out polyreaction.Polyoxyethylene glycol (molecular weight 6000) ester (MPEG) of 24g N-NSC 11448,12ml distillatory l-vinyl-2-pyrrolidone and 4g maleic anhydride is joined in about 2L water.In this, add 11.2ml N, and N '-methylene-bisacrylamide (MBA) aqueous solution [49mg/ml] and 8ml Tetramethyl Ethylene Diamine (the d=0.77 gram/ml).Made the solution degassing in 30 minutes through bubbling nitrogen.Add 8ml ferrous ammonium sulphate (0.5%w/v) aqueous solution and 12ml ammonium persulphate (80%w/v) aqueous solution then, and under continuous bubbling nitrogen, continue reaction 3 hours.In water-bath,, 80rpm carrying out polymerization under 34 ℃ under shaking.
Said solution is packed in the dialysis tubing and fallen in the water (dialysis medium).Dialysis was carried out 24 hours and was changed primary water.After 24 hours, take off solution and freeze-drying in round-bottomed flask in the dialysis tubing.
Utilize anti-phase RP-18 (C-18) post [Lichrospher RP-18e, 5 μ, 250mm * 4mm] through the residual monomer in Agilent 1100 serial HPLC system's detections and the quantifying polymers, especially residual VP and NIPAM.Used moving phase is the mixture of 80: 20 ratios of water and acetonitrile, and flow velocity is 1ml/ minute, and sampling volume is 50 μ l.Be 10 minutes working time, and column temperature is 30 ℃, and detecting wavelength is 226nm.Under these conditions, the RT of NIPAM is about 3 minutes, and the RT of VP is about 5 minutes.
Analytical data: residual monomer %i) NIPAM=0.066% (660ppm) and ii) VP=0.011% (110ppm).
Embodiment-1
Utilize percolation process to prepare polymkeric substance
In two 5L Glass Containerss, carry out the polyreaction of the batch weight of 160g (4L * 2) polymkeric substance.In each container, polyoxyethylene glycol (molecular weight 6000) ester (MPEG) of 48g N-NSC 11448,23ml distillatory l-vinyl-2-pyrrolidone and 8g maleic anhydride is joined in about 4L water.In this, add 22.4ml N, N '-methylene-bisacrylamide (MBA) aqueous solution [49mg/ml] and 16ml Tetramethyl Ethylene Diamine.Made the solution degassing in 30 minutes through bubbling nitrogen.Add 16ml ferrous ammonium sulphate (0.5%w/v) aqueous solution and 24ml ammonium persulphate (80%w/v) aqueous solution then and under continuous bubbling nitrogen, continue reaction 3 hours.In water-bath,, 80rpm carrying out polymerization under 34 ℃ under shaking.Between polymerization period, in due course between point (0,15,60 and 180 minute) take out sample and be used for reaction monitoring.
After polymerization is accomplished, through the disposable DPS-5101AA-201 type 0.2 μ m poly (ether sulfone) film 1 of sterilization in advance " bag type filter (0.8 and 0.2 μ m aperture) (manufacturers: AdvancedMicrodevices Pvt.Ltd, India) filters said solution.Merge the filtering content in two reaction vessels and utilize Proflux M12 (Millipore) diafiltration equipment to carry out tangential flow filtration to remove residual monomer impurity and other low molecular weight impurities.Through diafiltration the 8L reaction mixture that merges is concentrated into about 2.2L earlier, uses the enriched material of the high purity water diafiltration gained of about 30L then.During the diafiltration, reaction mixture is concentrated into about 1L.The diafiltration overall treatment time of 160g (8L) batch weight is about 4～6 hours.Then with the solution freeze-drying of diafiltration.
Utilize anti-phase RP-18 (C-18) post [Lichrospher RP-18e, 5 μ, 250mm * 4mm] through the residual monomer in Agilent 1100 serial HPLC system's detections and the quantifying polymers, especially residual VP and NIPAM.Used moving phase is the mixture of 80: 20 ratios of water and acetonitrile, and flow velocity is 1ml/ minute, and sampling volume is 50 μ l.Be 10 minutes working time, and column temperature is 30 ℃, and detecting wavelength is 226nm.Under these conditions, the RT of NIPAM is about 3 minutes, and the RT of VP is about 5 minutes.
Analytical data: residual monomer %i) NIPAM=＜0.001% (＜10ppm) with ii) VP=＜0.001% (＜10ppm).
Polymkeric substance has following spectrum signature, promptly
1H NMR (300MHz, Bruker spectrophotometer, CDCl 3, δ pm): 1.15 (broad peak ,-CH (CH 3) 2); 1.45 (broad peak ,-CH 2-CH-N (VP-ring); 1.63 (broad peak ,-CH 2-CHC (=O) NH); 1.99 (broad peak ,-CHC (=O) NH-), CH 2(VP ring), 2.36 (CH 2, the VP ring), 3.0 (O-CH 2-CH 2-), 3.23 (CH 2-N-); 3.62-3.66 (Br, CH 2, MPEG); 3.72 (NH-CH (CH 3) 2); 3.97 (Br, CH)
13C NMR (300MHz, Bruker spectrophotometer, CDCl 3, δ ppm): 174 (C=O); 76.6-77.6 (CDCl 3Multiplet with CH on the main polymer chain), the 70.6 (CH of MPEG 2), 41.6 (the unitary CH of sec.-propyl), the 31.8 (CH of main polymer chain 2), the 22.6 (CH of sec.-propyl 3)
FTIR (KBr bead, cm -1): 3500 (s, OH); 3296 (s, NH, secondary amide), 2972-2933 (s, CH, CH 2, CH 3), 1546 (s, the C=O of the NH flexural vibration of acid amides II and possible free acid, weak), 1387,1367 (sec.-propyl bimodal, CH 3, distortion), and 1172-1129 (m, O-C-O)
Embodiment-2
Taxol nanoparticle preparation of drug combination (rebuild and in small volume, promptly be up to 40ml)
A] preparation of taxol alcoholic solution (20mg/ml): the 200mg taxol is dissolved in the 10.0ml ethanol.
B] preparation of aqueous concentrates of polymkeric substance and vehicle: polymkeric substance, 66.7mg Sodium desoxycholate and 100mg Trisodium Citrate that 100mg is obtained by embodiment-1 are dissolved in the 10ml water and obtain clear soln.
C] preparation of taxol nanoparticle (0.6mg/ml): with 1.0ml step B] the aqueous concentrates of polymkeric substance and vehicle be dissolved in 31.3ml 10% dextrose solution and obtain clear soln.Syringe needle through internal diameter 0.330mm in 4 seconds with the 1.0ml steps A] the taxol alcoholic solution join and obtain the taxol nanoparticle that concentration is 0.6mg/ml in the above-mentioned solution.
The pharmaceutical composition of preparation has following characteristics thus:
Diluted fluid Polymer concentration (mg/ml) Septochol na concn (mg/ml) Sodium citrate concentration (mg/ml) Taxol concentration (mg/ml) Particle size (nm) Stability
10% Vadex 0.3 0.2 0.3 0.6 ≈80 ＞24 hours
Embodiment-3
Taxol nanoparticle preparation of drug combination (rebuild in big volume and promptly be up to 500ml)
A] preparation of taxol alcoholic solution (20mg/ml): the 400mg taxol is dissolved in the 20.0ml ethanol.
B] preparation of aqueous concentrates of polymkeric substance and vehicle: polymkeric substance, 133.4mg Sodium desoxycholate and 200mg Trisodium Citrate that 200mg is obtained by embodiment-1 are dissolved in the 20ml water and obtain clear soln.
C] preparation of taxol nanoparticle (0.6mg/ml): with 15.0ml step B] the aqueous concentrates of polymkeric substance and vehicle be dissolved in 500ml 10% dextrose solution and obtain clear soln.Syringe needle through internal diameter 0.711mm in 8 seconds with the 15.0ml steps A] the taxol alcoholic solution join and obtain the taxol nanoparticle that concentration is 0.6mg/ml in the above-mentioned solution.
The pharmaceutical composition of preparation has following characteristics thus:
Diluted fluid Polymer concentration (mg/ml) Septochol na concn (mg/ml) Sodium citrate concentration (mg/ml) Taxol concentration (mg/ml) Particle size (nm) Stability
10% Vadex 0.3 0.2 ?0.3 0.6 ≈85 ＞24 hours
Embodiment-4
The preparation of betulinic acid derivative [MJ-1098 of formula (II)] nanoparticle pharmaceutical compositions
A] preparation of MJ-1098 solution (15mg/ml): MJ-1098 (15mg) is dissolved in the mixture of 0.15ml DMAC N,N, 0.01ml Polysorbate 80, and in above-mentioned solution, adds 0.84ml ethanol and ultrasonic dissolution.
B] preparation of aqueous concentrates of polymkeric substance and vehicle: polymkeric substance, 6.67mg Sodium desoxycholate and 10mg Trisodium Citrate that 10mg is obtained by embodiment-1 are dissolved in the 1ml water and obtain clear soln.
C] preparation of MJ-1098 nano particle (0.75mg/ml): with 0.3ml step B] the aqueous concentrates of polymkeric substance and vehicle be dissolved in 9.2ml 5% dextrose solution and obtain clear soln.Syringe needle through internal diameter 0.330mm in 3 seconds with the 0.5ml steps A] MJ-1098 solution join and obtain the MJ-1098 nano particle that concentration is 0.75mg/ml in the above-mentioned solution.
The pharmaceutical composition of preparation has following characteristics thus:
Diluted fluid Polymer concentration (mg/ml) Septochol na concn (mg/ml) Sodium citrate concentration (mg/ml) Mj-1098 concentration (mg/ml) Particle size (nm) Stability
5% Vadex 0.3 0.2 0.3 0.75 ≈62 ＞24 hours
Embodiment-5
The preparation of betulinic acid derivative [DRF-4012 of formula (III)] nanoparticle pharmaceutical compositions
A] preparation of DRF-4012 solution (20mg/ml): MJ-DRF-4012 (20mg) is dissolved in 0.01ml Polysorbate 80 and the 0.99ml alcoholic acid mixture and passes through ultrasonic dissolution.
B] preparation of aqueous concentrates of polymkeric substance and vehicle: polymkeric substance, 6.67mg Sodium desoxycholate and 10mg Trisodium Citrate that 10mg is obtained by embodiment-1 are dissolved in the 1ml water and obtain clear soln.
C] preparation of DRF-4012 nano particle (0.60mg/ml): with 0.33ml step B] the aqueous concentrates of polymkeric substance and vehicle be dissolved in 10.44ml 5% dextrose solution and obtain clear soln.Syringe needle through internal diameter 0.305mm in 3 seconds with the 0.33ml steps A] DRF-4012 solution join and obtain the DRF-4012 nano particle that concentration is 0.6mg/ml in the above-mentioned solution.
The pharmaceutical composition of preparation has following characteristics thus:
Diluted fluid Polymer concentration (mg/ml) Septochol na concn (mg/ml) Sodium citrate concentration (mg/ml) DRF-4012 concentration (mg/ml) Particle size (nm) Stability
5% Vadex 0.3 0.2 0.3 0.6 ≈70 ＞24 hours
Embodiment-6
The preparation of betulinic acid derivative [DRF-4015 of formula (IV)] nanoparticle pharmaceutical compositions
A] preparation of DRF-4015 solution (20mg/ml): MJ-DRF-4015 (20mg) is dissolved in 0.01ml Polysorbate 80 and the 0.99ml alcoholic acid mixture and passes through ultrasonic dissolution.
B] preparation of aqueous concentrates of polymkeric substance and vehicle: polymkeric substance, 6.67mg Sodium desoxycholate and 10mg Trisodium Citrate that 10mg is obtained by embodiment-1 are dissolved in the 1ml water and obtain clear soln.
C] preparation of DRF-4015 nano particle (0.60mg/ml): with 0.33ml step B] the aqueous concentrates of polymkeric substance and vehicle be dissolved in 10.44ml 5% dextrose solution and obtain clear soln.Syringe needle through internal diameter 0.330mm in 4 seconds with the 0.33ml steps A] DRF-4015 solution join and obtain the DRF-4015 nano particle that concentration is 0.6mg/ml in the above-mentioned solution.
The pharmaceutical composition of preparation has following characteristics thus:
Diluted fluid Polymer concentration (mg/ml) Septochol na concn (mg/ml) Sodium citrate concentration (mg/ml) DRF-4015 concentration (mg/ml) Particle size (nm) Stability
5% Vadex 0.3 0.2 0.3 0.6 ≈46 ＞24 hours
Embodiment-7
The preparation of docetaxel nanometer particle medicinal composition
A] preparation of docetaxel alcoholic solution (40mg/ml): the 200mg docetaxel is dissolved in the 5.0ml ethanol.
B] preparation of aqueous concentrates of polymkeric substance and vehicle: polymkeric substance, 400mg Sodium desoxycholate and 400mg Trisodium Citrate that 400mg is obtained by embodiment-1 are dissolved in the 10ml water and obtain clear soln.
C] preparation of docetaxel nanometer particle (0.5mg/ml): with 4.0ml step B] the aqueous concentrates of polymkeric substance and vehicle be dissolved in 35.5ml 10% dextrose solution and obtain clear soln.Syringe needle through internal diameter 0.330mm in 3 seconds with the 0.5ml steps A] the docetaxel alcoholic solution join and obtain the docetaxel nanometer particle that concentration is 0.5mg/ml in the above-mentioned solution.
The pharmaceutical composition of preparation has following characteristics thus:
Diluted fluid Polymer concentration (mg/ml) Septochol na concn (mg/ml) Sodium citrate concentration (mg/ml) Docetaxel concentration (mg/ml) Particle size (nm) Stability
10% Vadex 4.0 ?4.0 ?4.0 0.5 ≈125 ＞24 hours
Embodiment-8
The preparation of VP nanoparticle pharmaceutical compositions
A] preparation of VP solution (20mg/ml): ultrasonicly down the 20mg VP is dissolved in 0.10ml DMAC N,N and the 0.90ml alcoholic acid mixture.
B] preparation of aqueous concentrates of polymkeric substance and vehicle: polymkeric substance, 6.67mg Sodium desoxycholate and 10mg Trisodium Citrate that 10mg is obtained by embodiment-1 are dissolved in the 10ml water and obtain clear soln.
C] preparation of VP nano particle (0.6mg/ml): with 0.3ml step B] the aqueous concentrates of polymkeric substance and vehicle be dissolved in 9.4ml 5% dextrose solution and obtain clear soln.Syringe needle through internal diameter 0.330mm in 3 seconds with the 0.3ml steps A] the VP alcoholic solution join and obtain the VP nano particle that concentration is 0.6mg/ml in the above-mentioned solution.
The pharmaceutical composition of preparation has following characteristics thus:
Diluted fluid Polymer concentration (mg/ml) Septochol na concn (mg/ml) Sodium citrate concentration (mg/ml) VP concentration (mg/ml) Particle size (nm) Stability
5% Vadex 0.3 0.2 0.3 0.6 ≈50 ＞24 hours
Embodiment-9
[ 14C] polymkeric substance of mark is in the mensuration of mouse Chinese traditional medicine kinetics, bio distribution and elimination
The male Swiss albino mouse of 30 6～8 ages in week, heavily about 25～30 grams is divided into 5 groups at random, forms by 6 animals for every group.Will [ 14C] polymkeric substance of mark is diluted to the 5mg/ml based on the polymkeric substance specific activity in deionized water.All animals through intravenous injection accept single dose 40mg/kg [ 14C] polymkeric substance.
In pharmacokinetic study, anesthesia is down got blood and is collected 100 μ l blood from animal to the pipe that contains EDTA after the time point of using back 3 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 16 hours and 24 hours is through eye socket.For draining research, from metabolic cage or force and collect urine and ight soil (10 minutes).Collect suprarenal gland, brain, lung, liver, the heart, kidney, spleen, stomach, small intestine, large intestine, ight soil, urine, bladder, eye, skin, skin, leg muscle, testing and epididymis, wash, cut and weigh (10 minutes, 60 minutes, 24 hours and 48 hours) during end.
Through merge in 50 μ l blood/urine and 5ml liquid scintillation mixture determining blood and the urine [ 14C] polymer concentration.Merge before 500 μ l blood/urine and the 5ml liquid scintillation mixture, in deionized water with ight soil and tissue (being no more than 0.5 restrains) homogenization to obtain 20% homogenate.Through liquid scintillation analyser analytic sample.Based on linear and quencher curve, with cpm (CPM) convert into μ g/ml calculating [ 14C] amount of polymkeric substance.
Radioactivity haemoconcentration curve display diphasic curve, the weak point with 0.448 ± 0.157 hour (26.88 minutes) is eliminated transformation period T 1/2(β) with 54.7ml/ hour quick clearance rate.
The leading approach of find eliminating be urine (48 hours, urine: 66.91%, ight soil: 17.39%) and the data collection of collecting up to 48 hours account for injected radioactive 84.87%.Tissue distribution can be ignored.Find that kidney, liver, skin and intestines are target organs.Yet the level of polymkeric substance in tissue removed through urine and ight soil fast.
In showing the radioactive kidney of highest level, liver, skin and intestines, tissue distribution can be ignored.Yet the level of polymkeric substance in tissue removed through urine and ight soil fast.
In a word, this research shows that polymkeric substance eliminates rapidly and vital organ, do not deposit in body.Though the known polymer right and wrong are biodegradable, mainly show that through removing fast and effectively of urine said polymkeric substance is safe and useful for human use.
Embodiment-10
In the rabbit medium sized vein, inject and use the 125mg/kg polymkeric substance is measured site of administration in the time of 5 days possible local toxicity (if having)
Disposable syringe and the 23G syringe needle that uses 5ml with concentration as 75mg/ml in 10% Vadex, tried the thing intravenous administration in the auricular vein of the auris dextra of every rabbit, every day 125mg/kg, continuous 5 days.Left side ear is with comparing and accepting 10% Vadex with identical approach.The administration volume is adjusted to and is no more than the 3.5ml/kg the weight of animals.From the 1st day to the 5th day, the periodicity that every day, the time point 5 minutes, 10 minutes, 30 minutes, 60 minutes and 24 hours carried out local toxicity in the injection site was observed.At the 7th day, examination of living tissue is got in the injection site punching of two ears of all 6 rabbits.
Cause slightly thrombophlebitis in the injection site of the rabbit of injection 10% Vadex with the polymkeric substance of dosage continuous 5 days intravenous administration 75mg/ml in rabbit ear vein of 125mg/kg to moderate.The dosage of the selected polymkeric substance of deducibility does not cause any local toxicity in site of administration.
Embodiment-11
In Wistar rat medium sized vein, inject and use the 400mg/kg polymkeric substance and measure especially possible target organ toxicity in the time of 5 days to the capillary blood vessel system
Disposable syringe and 23G syringe needle with 5ml will be dissolved in thing arrives every rat with the 400mg/kg intravenous administration the tail intravenously that tried in 10% Vadex.Control animal is only accepted 05 Vadex with identical approach.The administration volume is adjusted to the 5ml/kg the weight of animals.Periodically observe (handling the back the 7th, 14 and 21 day) spinoff (general inspection and laboratory parameters) and write down mortality ratio.All animals all are condemned to death and postmortem.
Under study condition, use polymkeric substance with 5 days intravenous push of dosage level of 400mg/kg body weight, in being processed rat, do not produce any mortality ratio or toxic sign of any health or symptom.
Whose body weight of rat and mean body weight all show stable increase in polymer treatment group and the control group.The body weight that is processed animal is compared with contrast and is not observed significant difference.
In utilizing the rat of polymer treatment, hematologic parameter all is in the NL in whole research.The total bilirubin (p=0.0471) that organize mid-term when detecting baseline and the gross protein (p=0.0005) of uric acid (p=0.0157) and final treated animal are compared with control animal with uric acid (p=0.0404) has significant difference.Yet all values is all in NL.
The photo-reactive degree is measured (Photoactometer) test and is shown respectively the locomotor activity there was no significant difference between the 7th day and the 21st day control group and treatment group, and the prompting polymkeric substance does not have any neurotoxicity.
Treatment group shows similar histologic characteristics with the control group sample.All research organs all show normal configuration under light microscopy.Scrutiny in each organ the capillary blood vessel system and in any organ, all do not find pathological characteristics.In addition, in the capillary blood vessel system of polymer treatment animal, do not change.
According to above observation, visible polymkeric substance is used with the 400mg/kg body weight and was not caused any general toxicity or any significant haematics toxicity in continuous 5 days.Yet the total bilirubin of finding in the time of the 21st day to compare with control group final group is significantly higher.
Embodiment-12
Measure the possible target organ toxicity that especially is directed against the capillary blood vessel system when single intravenous push is used the 800mg/kg polymkeric substance in the Wistar rat
To be dissolved in thing is administered to every rat with 800mg/kg the tail intravenously that tried in 10% Vadex with 1ml disposable syringe and 26G syringe needle.Control animal is only accepted 10% Vadex with identical approach.The administration volume is adjusted to the 5ml/kg the weight of animals.Periodically observe (handling the back the 1st, 3 and 7 day) spinoff (general inspection and laboratory parameters) and write down mortality ratio.All animals all are condemned to death and postmortem.
Under study condition, use polymkeric substance with the dosage level single intravenous push of 800mg/kg body weight, in rat, do not produce any mortality ratio or any observable toxicity sign or symptom.
Whose body weight of rat and mean body weight all show stable increase in polymer treatment group and the control group.In utilizing the rat of polymer treatment, hematologic parameter all is in the NL in whole research.In utilizing the rat of polymer treatment, biochemical parameters all is in the NL in whole research.Histopathological study shows there was no significant difference between control rats and the treatment group rat.The Photomicrograph of injection back the 3rd day and the polymer treatment rat of putting to death in the 7th day is presented at all 4 and checks the variation that does not all have tangible capillary blood vessel system in the organs (brain, eye, kidney and skin).
According to above observation, the polymkeric substance of visible 800mg/kg body weight dosage does not cause the variation of any general toxicity or any significant hematology and biological chemistry toxicity or capillary blood vessel system and can think that be safe when intravenous administration is given rat.
Embodiment-13
Measure the possible local toxicity (if having) of polymkeric substance site of administration (subcutaneous) in the rabbit
With the disposable syringe of 1ml and 23G syringe needle 0.1ml is dissolved in being tried during auris dextra that the thing single subcutaneous injection is administered to 6 every rabbits in the rabbit hangs down in 10% Vadex with the concentration of 75mg/ml.The left ear-lobe of all 6 rabbits is with comparing and accepting the 0.1ml10% Vadex with identical approach.Observe 5 minutes, 10 minutes, 30 minutes, 60 minutes and the periodicity of carrying out local toxicity in 24 hours in the injection site.
When injection was tested after 48 hours, the polymkeric substance of single subcutaneous administration 100 μ l 75mg/ml or 100 μ l Vadexs caused mild inflammation in the injection site in the rabbit ear.The selected polymkeric substance of deducibility does not cause any local toxicity in site of administration after subcutaneous administration.
Embodiment-14
Measure 6 months dosage toxicity of approach polymkeric substance in the rat medium sized vein
Use polymkeric substance used in the nanoparticle formulations with the dosage level that is equivalent to the 10mg/kg medicine.In 180 days time periods (about 26 weeks) per three Monday second periodicity ground in the lateral tail vein medium sized vein, use Vadex (10%) to control group.Observation comprises consumption, clinical labororatory's research, organ weight and the histopathology of mortality ratio, clinical indication, body weight, food and water.
Treatment group and control animals be all maintenance activities prevailingly and healthy during studying.Except several owing to infect die unexpectedly, in treatment group and control group less than the death not relevant with processing.The consumption that the body weight of two other animals of individual character all demonstrates food during progressively increasing of body weight and the research or water does not change.The hematologic parameter of the male and female Wistar rats of report is all in normal range.Yet in treatment group, the male WBC and the counting of neutrophil leucocyte and female neutrophil leucocyte counting slightly reduce, but still in NL.In treatment group and control group, all notice the small size increase of Reticulocyte counting.
The haemobiochemistry parameter of the male and female Wistar rats of report is all in normal range.The glucose, ALP and the creatinine that slightly change the male and female Wistar rats that comprises treatment group and control group slightly are higher than normal value.The visible male triglyceride level of treatment group slightly increases in the time of 6 months.Male and female urine parameter is all in NL.

Claims (102)

  1. One kind contain three kinds of monomeric units pass through the crosslinked high-purity polymer of bifunctional ethenyl derivatives; Said monomeric unit is selected from the ester (MPEG) of 1-vinyl pyrrolidone (VP), N-NSC 11448 (NIPAM) and maleic anhydride and polyoxyethylene glycol, in the said polymkeric substance separately the content of toxicity monomer impurity less than 0.001%.
  2. 2. according to the high-purity polymer of claim 1, wherein said bifunctional vinyl linking agent is N, N '-methylene-bisacrylamide (MBA).
  3. 3. according to the high-purity polymer of claim 1, the content of said polymkeric substance toxic 1-vinyl pyrrolidone (VP) is less than 0.001%.
  4. 4. according to the high-purity polymer of claim 1, the content of said polymkeric substance toxic N-NSC 11448 (NIPAM) is less than 0.001%.
  5. 5. according to the polymkeric substance of claim 1, wherein said monomeric weight ratio NIPAM: VP is 55: 22～65: 35.
  6. 6. according to the polymkeric substance of claim 5, wherein said monomeric weight ratio NIPAM: VP is 58: 32～62: 28.
  7. 7. according to the polymkeric substance of claim 1, wherein monomeric weight ratio (NIPAM+VP): MPEG is 90: 10～95: 5.
  8. 8. according to the polymkeric substance of claim 1, wherein monomeric weight ratio (NIPAM+VP): MPEG is 80: 20～95: 5.
  9. 9. according to the polymkeric substance of claim 1, its 13Has the peak that δ is following value in the C NMR spectrum: 174,76.6-77.6,70.6,41.6,31.8 and 22.6.
  10. 10. according to the polymkeric substance of claim 1, its 11.14,1.45,1.63,1.99,2.36,3.0,3.23,3.62-3.66,3.72 and 3.97 has the peak that δ is following value in the H NMR spectrum:.
  11. 11., have cm in its FT-IR spectrum according to the polymkeric substance of claim 1 -13500,3296,2972-2933,1546,1387,1367 and 1172-1129 frequency for following value:.
  12. 12. according to the polymkeric substance of claim 1, it has the structure of formula (I)
    Figure FSB00000453619500021
  13. 13. according to the polymkeric substance of claim 1, it is biocompatible.
  14. 14. according to the polymkeric substance of claim 1, its right and wrong are biodegradable.
  15. 15. according to the polymkeric substance of claim 1, it is nontoxic.
  16. 16. according to the polymkeric substance of claim 1, its T 1/2(K10) value is 0.152 ± 0.018 hour.
  17. 17. according to the polymkeric substance of claim 1, its T 1/2(α) value is 0.065 ± 0.014 hour.
  18. 18. according to the polymkeric substance of claim 1, its T 1/2(β) value is 0.448 ± 0.0157 hour.
  19. 19. according to the polymkeric substance of claim 1, its C MaxValue is 82.96 ± 5.11 μ g/ml.
  20. 20. according to the polymkeric substance of claim 1, its TG-AUC (AUC) value is 18.29 ± 1.62 hours * μ g/ml.
  21. 21. according to the polymkeric substance of claim 1, its clean-up time (CL) value is 54.67 ± 4.86ml/ hour.
  22. 22. according to the polymkeric substance of claim 1, its mean residence time (MRT) value is 0.465 ± 0.13 hour.
  23. 23. according to the polymkeric substance of claim 1, its stable state lower volume distribution (Vss) value is 25.43 ± 5.2ml/ hour.
  24. 24. according to the polymkeric substance of claim 1, it is eliminated from urine, ight soil, tissue and washing fluid (rinse).
  25. 25. according to each polymkeric substance in the claim 1 and 24, it is mainly from urine and ight soil elimination.
  26. 26. according to each polymkeric substance in the claim 1 and 24, wherein 67% polymkeric substance was eliminated from urine using in back 48 hours.
  27. 27. according to each polymkeric substance in the claim 1 and 24, wherein 17% polymkeric substance was eliminated from ight soil using in back 48 hours.
  28. 28. according to each polymkeric substance in the claim 1 and 24, wherein 84% polymkeric substance was eliminated from urine, ight soil, tissue and washing fluid using in back 48 hours.
  29. 29. according to the polymkeric substance of claim 1, wherein in the rabbit ear behind the said aqueous solutions of polymers of subcutaneous administration 48 hours said polymkeric substance do not cause any local toxicity in site of administration.
  30. 30. according to the polymkeric substance of claim 1, wherein in the rabbit ear vein medium sized vein, use said aqueous solutions of polymers after 24 hours said polymkeric substance do not cause any local toxicity in site of administration.
  31. 31. according to the polymkeric substance of claim 1, wherein when using to the Wistar rat through the intravenous push approach in continuous at the most 5 days with the dosage of 400mg/kg～800mg/kg, said polymkeric substance does not cause any general toxicity.
  32. 32. according to the polymkeric substance of claim 1, wherein when using to the Wistar rat through the intravenous push approach in continuous at the most 5 days with the dosage of 400mg/kg～800mg/kg, said polymkeric substance does not cause any significant haematics toxicity.
  33. 33. highly purified comprise three kinds of the ester (MPEG) that is selected from 1-vinyl pyrrolidone (VP), N-NSC 11448 (NIPAM) and maleic anhydride and polyoxyethylene glycol monomeric [ 14C]-polymkeric substance of mark, wherein said monomeric weight ratio NIPAM: VP is 58: 32～62: 28, and monomeric be 80: 20～95: 5 than (NIPAM+VP): MPEG.
  34. 34. one kind be used to prepare according to the high purity of claim 1 and separately the content of toxicity monomer impurity may further comprise the steps less than the method for 0.001% polymkeric substance:
    I) an amount of said three kinds of monomer NIPAM, VP and MPEG are dissolved in the water;
    Ii) to step I) solution in add proper amount of cross-linking agent and acvator in succession;
    Iii) to step I i) solution in bubbling rare gas element 30～60 minutes;
    Iv) in step I solution v), add an amount of acvator and polymerization starter;
    V) under 25 ℃～45 ℃ temperature, polymerization procedure solution iv) is 3～6 hours under inert gas atmosphere;
    Vi) filtrate through the strainer filtration step solution v) and the collection of sterilization in advance;
    Vii) step filtrating is vi) carried out diafiltration and collected filtrating;
    Viii) randomly step filtrating is vii) carried out extra diafiltration steps and collected filtrating; With
    Ix) randomly with step vii) or filtrating freeze-drying viii) to obtain the lyophilized powder of polymkeric substance.
  35. 35. according to the method for claim 34, wherein said monomeric ratio NIPAM: VP is 55: 22～65: 35, and monomeric weight ratio (NIPAM+VP): MPEG is 90: 10～95: 5.
  36. 36. according to the method for claim 34, wherein said monomeric weight ratio NIPAM: VP is 58: 32～62: 28, and said monomeric weight ratio (NIPAM+VP): MPEG is 80: 20～95: 5.
  37. 37. according to the method for claim 34, wherein said linking agent is the bifunctional ethenyl derivatives.
  38. 38. according to the method for claim 37, wherein said bifunctional ethenyl derivatives is N, N '-methylene-bisacrylamide.
  39. 39., wherein use said linking agent with the amount of 1.3～1.5%w/w of total monomer content according to the method for claim 34.
  40. 40., wherein use said linking agent with the amount of 1.35～1.4%w/w of total monomer content according to the method for claim 39.
  41. 41. according to the method for claim 34, wherein said acvator is selected from one of Tetramethyl Ethylene Diamine and ferrous ammonium sulphate or both combinations.
  42. 42., wherein use said acvator with the amount of 15～18%w/w of total monomer content according to the method for claim 34.
  43. 43., wherein use said acvator with the amount of 15～16%w/w of total monomer content according to the method for claim 42.
  44. 44. method according to claim 34; Wherein said polymerization starter is to be selected from following at least a or multiple peroxide cpd: diacyl peroxide, Lucidol, diacetyl peroxide, dialkyl peroxide, tert-butyl peroxide and t-amyl peroxy thing or based on the polymerization starter 2 of nitrile, 2 '-Diisopropyl azodicarboxylate (AIBN); Perhaps based on the polymerization starter ammonium peroxydisulfate or the ammonium persulphate of inorganic salt.
  45. 45. according to the method for claim 44, wherein said polymerization starter is ammonium peroxydisulfate or ammonium persulphate.
  46. 46., wherein use said polymerization starter with the amount of 20～30%w/w of total monomer content according to the method for claim 34.
  47. 47., wherein use said polymerization starter with the amount of 23～25%w/w of total monomer content according to the method for claim 46.
  48. 48. according to the method for claim 34, wherein said rare gas element is argon gas or nitrogen.
  49. 49. according to the method for claim 34, wherein step in v) the used strainer of sterilization in advance be that the aperture is the disposable polyether sulfone film 1 of 0.8 and 0.2 μ m " bag type filter.
  50. 50. according to the method for claim 34, wherein step vi) and vii) used diafiltration equipment be the Proflux M12 diafiltration equipment that Millipore makes.
  51. 51. the polymkeric substance that the method through claim 34 obtains, the content of wherein said polymkeric substance toxic 1-vinyl pyrrolidone (VP) is less than 0.001%.
  52. 52. the polymkeric substance that the method through claim 34 obtains, the content of wherein said polymkeric substance toxic N-NSC 11448 (NIPAM) is less than 0.001%.
  53. 53. the polymkeric substance that the method through claim 34 obtains, its 13Has the peak that δ is following value in the C NMR spectrum: 174,76.6-77.6,70.6,41.6,31.8 and 22.6.
  54. 54. the polymkeric substance that the method through claim 34 obtains, its 11.14,1.45,1.63,1.99,2.36,3.0,3.23,3.62-3.66,3.72 and 3.97 has the peak that δ is following value in the H NMR spectrum:.
  55. 55. the polymkeric substance that the method through claim 34 obtains has cm in its FT-IR spectrum -13500,3296,2972-2933,1546,1387,1367 and 1172-1129 frequency for following value:.
  56. 56. the polymkeric substance that the method through claim 34 obtains, it has the structure of formula (I)
    Figure FSB00000453619500061
  57. 57. the polymkeric substance that the method through claim 34 obtains, it is biocompatible, non-biodegradable and nontoxic.
  58. 58. the polymkeric substance that the method through claim 34 obtains, its T 1/2(K10) value is 0.152 ± 0.018 hour, T 1/2(α) value is 0.065 ± 0.014 hour, T 1/2(β) value is 0.448 ± 0.0157 hour, C MaxValue is 82.96 ± 5.11 μ g/ml, and TG-AUC (AUC) value is 18.29 ± 1.62 hours * μ g/ml, and clean-up time (CL) value is 54.67 ± 4.86ml/ hour, and mean residence time (MRT) value is 0.465 ± 0.13 hour, stable state lower volume distribution (V Ss) value is 25.43 ± 5.2ml/ hour.
  59. 59. the polymkeric substance that the method through claim 34 obtains, wherein 84% polymkeric substance was eliminated from urine, ight soil, tissue and washing fluid using in back 48 hours.
  60. 60. the polymkeric substance that the method through claim 34 obtains, wherein in the rabbit ear behind the said aqueous solutions of polymers of subcutaneous administration 48 hours or in the rabbit ear vein medium sized vein, use said aqueous solutions of polymers after 24 hours said polymkeric substance do not cause any local toxicity in site of administration.
  61. 61. the polymkeric substance that the method through claim 34 obtains, wherein when using to the Wistar rat through the intravenous push approach in continuous at the most 5 days with the dosage of 400mg/kg～800mg/kg, said polymkeric substance does not cause any general toxicity or haematics toxicity.
  62. 62. medicine box; It comprises (a) and contains in water solubleness less than the medicine of the poorly water-soluble of 10mg/ml or a bottle of the solution of compound in water-miscible solvent or its mixture; High purity and the monomer foreign matter content that (b) contains claim 1 is less than another bottle of the solution of 0.001% polymkeric substance and pharmaceutically acceptable vehicle; Wherein (a) and (b) provide with 1: 1～1: 10 volume ratio, said medicine box are suitable for preparing and use to the medicine of the said poorly water-soluble of the patient's that these needs are arranged form of nanoparticles or the pharmaceutical composition of compound.
  63. 63. according to the medicine box of claim 62, the medicine of wherein said poorly water-soluble or compound are selected from carcinostatic agent, anti-inflammatory agent, anti-mycotic agent, antiemetic, hypotensive agent, sexual hormoue, steroid, microbiotic, narcotic or immunomodulator.
  64. 64. according to the medicine box of claim 63, wherein carcinostatic agent is selected from taxol, Taxane derivative that docetaxel is relevant with other; Irinotecan, the camptothecin derivative that TPT is relevant with other; Zorubicin, daunorubicin and relevant anthracycline derivatives; Cis-platinum; Oxaliplatin; 5 FU 5 fluorouracil; MTC; Methotrexate; VP; Betulinic ncid and verivate thereof; And Wedelolactone and verivate thereof.
  65. 65. according to the medicine box of claim 63, wherein anti-inflammatory agent is selected from indomethacin, Ibuprofen BP/EP, KP, FLURBIPROFEN USP24, piroxicam, tenoxicam and Naproxen Base.
  66. 66. according to the medicine box of claim 63, wherein anti-mycotic agent is selected from KETOKONAZOL and amphotericin B.
  67. 67. according to the medicine box of claim 63, wherein sexual hormoue is selected from testosterone, oestrogenic hormon, Progesterone and Theelin,dihydro-.
  68. 68. according to the medicine box of claim 63, wherein steroid is selected from DEXAMETHASONE BP98, prednisolone and triamcinolone.
  69. 69. according to the medicine box of claim 63, wherein hypotensive agent is selected from captopril, ramipril, terazosin, minoxidil and Prazosin.
  70. 70. according to the medicine box of claim 63, wherein antiemetic is selected from ondansetron and granisetron.
  71. 71. according to the medicine box of claim 63, wherein microbiotic is selected from metronidazole and fusidic acid.
  72. 72. according to the medicine box of claim 63, wherein immunomodulator is selected from ciclosporin and xenyl dimethyl-dicarboxylicacid.
  73. 73. according to the medicine box of claim 63, wherein narcotic is selected from Propofol, alfaxalone and Hexobarbital.
  74. 74. according to the medicine box of claim 64, wherein said betulinic acid derivative is selected from the MJ-1098 of formula (II), the DRF-4012 of formula (III) and the DRF-4015 of formula (IV)
  75. 75. according to the medicine box of claim 62, wherein said water-miscible solvent is selected from Viscotrol C or the glycerine and composition thereof of vegetables oil, the polyethoxylated of W 166, Polysorbate 80, Polysorbate 20, the polyethoxylated of ethanol, N, N,N-DIMETHYLACETAMIDE, DMSO 99.8MIN., diethyl sulfoxide, different molecular weight polyethylene glycol, different molecular weight.
  76. 76. according to the medicine box of claim 62, wherein said pharmaceutically acceptable vehicle is selected from Sodium desoxycholate, biliary salts; Polysorbate 80, Polysorbate 20, the vegetables oil of polyethoxylated; The Viscotrol C of polyethoxylated is selected from the polysaccharide of Vadex, sucrose, lactose and N.F,USP MANNITOL, the SPAN of different stage or spans; Different stage sell pool type, or the Prist of different stage, and composition thereof.
  77. 77. according to the medicine box of claim 76, wherein said pharmaceutically acceptable vehicle also comprises buffer reagent.
  78. 78. according to the medicine box of claim 77, wherein said buffer reagent is a Trisodium Citrate.
  79. 79. medicine box according to claim 62; If with the bottle of 1～5ml of smaller size smaller a) content join bottle b that contains for 35 times of its volumes) in the diluted fluid of content, then its randomly to comprise said diluted fluid and syringe and internal diameter be the syringe needle of 0.305～0.356mm; If with the bottle of 10～15ml of comparatively large vol a) content join bottle b that contains for 35 times of its volumes) in the diluted fluid of content, then its randomly to comprise said fluid and syringe and internal diameter be the syringe needle of 0.559～0.711mm.
  80. 80. the pharmaceutical composition of a form of nanoparticles; Be included in solubleness in the water less than the medicine of the poorly water-soluble of 10mg/ml or compound, water-miscible solvent, according to the polymkeric substance and the pharmaceutically acceptable vehicle of claim 1; All these materials are comprised in the diluted fluid, and said pharmaceutical composition is suitable for using the patient to needs.
  81. 81. 0 pharmaceutical composition according to Claim 8, the medicine of wherein said poorly water-soluble are given those in the aforementioned claim 63～74.
  82. 82. 0 pharmaceutical composition according to Claim 8, wherein said pharmaceutically acceptable vehicle are given those in the aforementioned claim 76～78.
  83. 83. 0 pharmaceutical composition according to Claim 8, wherein said water-miscible solvent are given those in the aforementioned claim 75.
  84. 84. 0 pharmaceutical composition according to Claim 8, wherein said diluted fluid be selected from water, salt solution, 5% and 10% dextrose solution, Vadex and sodium-chlor solution, sodium lactate solution, Lactated Ringer'S Solution, mannitol solution, N.F,USP MANNITOL and Vadex or sodium-chlor solution, ringer's solution, sodium chloride solution, sterile water for injection and contain the polycomponent electrolyte solution of the various combination of ionogen, Vadex, fructose and Nulomoline.
  85. 85. 0 pharmaceutical composition according to Claim 8, the medicine of wherein said poorly water-soluble or compound are embedded in the said polymer shell with form of nanoparticles.
  86. 86. 5 pharmaceutical composition according to Claim 8, the size of particles of wherein said form of nanoparticles is 30～150nm.
  87. 87. 0 pharmaceutical composition according to Claim 8, wherein used polymkeric substance is highly purified, has the structure of formula (I), contains content less than 0.001% monomer VP and NIPAM, at it 13Have the peak that δ is following value in the C NMR spectrum: 174,76.6-77.6,70.6,41.6,31.8 and 22.6, at it 11.14,1.45,1.63,1.99,2.36,3.0,3.23,3.62-3.66,3.72 and 3.97 has the peak that δ is following value in the H NMR spectrum:, in its FT-IR spectrum, have cm -13500,3296,2972-2933,1546,1387,1367 and 1172-1129 frequency for following value:.
  88. 88. 0 pharmaceutical composition according to Claim 8, wherein used polymkeric substance is highly purified, has the structure of formula (I), contains content less than 0.001% monomer VP and NIPAM, T 1/2(K10) value is 0.152 ± 0.018 hour, T 1/2(α) value is 0.065 ± 0.014 hour, T 1/2(β) value is 0.448 ± 0.0157 hour, C MaxValue is 82.96 ± 5.11 μ g/ml, and TG-AUC (AUC) value is 18.29 ± 1.62 hours * μ g/ml, and clean-up time (CL) value is 54.67 ± 4.86ml/ hour, and mean residence time (MRT) value is 0.465 ± 0.13 hour and stable state lower volume distribution (V Ss) value is 25.43 ± 5.2ml/ hour.
  89. 89. 0 pharmaceutical composition according to Claim 8, its pH is 6.0～8.5.
  90. 90. be used to prepare according to Claim 8 the method for pharmaceutical composition of medicine or compound of the poorly water-soluble of 0 form of nanoparticles, may further comprise the steps:
    I) preparation medicine/compound enriched material comprises the medicine of said poorly water-soluble or compound dissolution in suitable water-miscible solvent or its mixture;
    Ii) prepare the aqueous concentrates of said polymkeric substance and pharmaceutically acceptable vehicle, may further comprise the steps:
    A) at first the high purity of requirement and formula (I) polymkeric substance of toxicity NIPAM and VP content＜0.001% are joined in the proper amount of water for injection to obtain solution;
    B) pharmaceutically acceptable vehicle and buffer reagent are joined in the solution of said polymkeric substance in water;
    Iii) with step I ib) in solution mix with diluted fluid to obtain clear soln;
    Iv) utilizing internal diameter is the syringe needle of 0.305～0.356mm, in 4 seconds with step I) the smaller size smaller of solution join in the step I solution ii); Or
    V) utilizing internal diameter is the syringe needle of 0.559～0.711mm, in 10 seconds with step I) the comparatively large vol of solution join in the step I solution ii);
    Vi) with step I) injection of solution in step I solution ii), wherein add step I) the used syringe needle of solution should keep being immersed in the step I solution ii); With
    Vii) randomly, at injecting step i) solution during will accommodate step I solution ii) container remain on inverted position.
  91. 91. according to the method for claim 90, the medicine of wherein used poorly water-soluble is given those in the aforementioned claim 63～74.
  92. 92. according to the method for claim 90, wherein used pharmaceutically acceptable vehicle is given those in the aforementioned claim 76～78.
  93. 93. according to the method for claim 90, wherein used water-miscible solvent is given those in the aforementioned claim 75.
  94. 94. according to the method for claim 90, wherein used diluted fluid is given those in the aforementioned claim 84.
  95. 95. according to the method for claim 90, wherein said smaller size smaller according to step I solution v) is meant the step I of claim 90) the volume of 1～5ml of solution.
  96. 96. according to the method for claim 90, wherein said comparatively large vol according to step solution v) is meant the step I of claim 90) the volume of 10～15ml of solution.
  97. 97. according to the method for claim 90, wherein being embedded in the medicine of the poorly water-soluble in the said polymer shell or the size of particles of compound in the gained pharmaceutical composition is 30～150nm.
  98. 98. 0 pharmaceutical composition according to Claim 8, it is given through intravenously, intramuscular or subcutaneous administration has the patient who needs.
  99. 99. 0 pharmaceutical composition according to Claim 8, wherein used polymkeric substance is highly purified, has the structure of formula (I) and contains content less than 0.001% monomer VP and NIPAM, and it is safety non-toxic that said pharmaceutical composition is used humans.
  100. 100. the pharmaceutical composition of claim 80 is used for treating the purposes of medicine of medicine or the humans pathological condition that compound can be treated of the said poorly water-soluble of claim 63～74 in preparation.
  101. 101. according to the purposes of claim 100, wherein said medicine is formulated into through intravenously, intramuscular or subcutaneous injection and uses.
  102. 102., comprise intravenously, intramuscular or subcutaneous injection according to the purposes of claim 101.
CN2006800519727A 2005-12-28 2006-12-26 A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions Expired - Fee Related CN101336256B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1190KO2005 2005-12-28
IN1190/KOL/2005 2005-12-28
PCT/IN2006/000504 WO2007074476A1 (en) 2005-12-28 2006-12-26 A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CN101336256A CN101336256A (en) 2008-12-31
CN101336256B true CN101336256B (en) 2012-03-28

Family

ID=37845115

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800519727A Expired - Fee Related CN101336256B (en) 2005-12-28 2006-12-26 A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions

Country Status (19)

Country Link
US (2) US8338562B2 (en)
EP (2) EP2172497B1 (en)
JP (1) JP2009522251A (en)
KR (2) KR20080091158A (en)
CN (1) CN101336256B (en)
AR (1) AR058866A1 (en)
AT (1) ATE529454T1 (en)
AU (1) AU2006329554C1 (en)
BR (1) BRPI0620745A2 (en)
CA (1) CA2635469A1 (en)
EA (1) EA017682B1 (en)
ES (2) ES2375740T3 (en)
HK (1) HK1123814A1 (en)
IL (1) IL192423A0 (en)
MX (1) MX2008008423A (en)
MY (1) MY148575A (en)
NZ (1) NZ569372A (en)
WO (1) WO2007074476A1 (en)
ZA (1) ZA200806548B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007074476A1 (en) 2005-12-28 2007-07-05 Dabur Pharma Limited A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
JP5420946B2 (en) * 2009-03-23 2014-02-19 富士フイルム株式会社 Minoxidil aqueous composition containing bile acids
CN101845120B (en) * 2010-03-25 2011-11-16 淮阴师范学院 Method for synthesizing temperature-sensitive and biodegradable in situ gel
US8772355B2 (en) 2010-11-23 2014-07-08 Howard University Stealth polymeric particles for delivery of bioactive or diagnostic agents
US8921429B2 (en) 2010-11-23 2014-12-30 Howard University Biodegradable stealth polymeric particles fabricated using the macromonomer approach by free radical dispersion polymerization
PT2782584T (en) 2011-11-23 2021-09-02 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20160066563A1 (en) * 2012-06-07 2016-03-10 David Moscatello Compositions and methods for collecting, washing, cryopreserving, recovering and return of lipoaspirates to physician for autologous adipose transfer procedures
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (en) 2014-05-22 2016-10-12 Therapeuticsmd Inc PHARMACEUTICAL COMPOSITION OF ESTRADIOL AND PROGESTERONE FOR HORMONAL REPLACEMENT THERAPY
EP3151838A4 (en) * 2014-06-04 2017-11-29 Izard, Ryan Methods and compositions for orally dosing postnatal swine
CN104119474B (en) * 2014-06-26 2016-06-15 中国人民解放军第三○九医院 A kind of surface-functionalized micro-nano polymeric hollow particle and preparation method thereof
CN104119475B (en) * 2014-06-26 2016-06-15 中国人民解放军第三○九医院 A kind of surface-functionalized micro-nano polymer gel particle and preparation method thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10176182B2 (en) 2015-08-31 2019-01-08 International Business Machines Corporation File deletion in storage devices based on the deletion priority rules
EP3153227A1 (en) * 2015-10-07 2017-04-12 Evonik Degussa GmbH Method for the preparation of polyalkenamers for packaging applications
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896025A2 (en) * 1997-08-05 1999-02-10 Stefano Gasparini Non-toxic plastic material having adsorbency and absorbency properties, and corresponding process for its manufacture
US6322817B1 (en) * 1999-02-17 2001-11-27 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US636519A (en) 1899-04-14 1899-11-07 Elisha Gray Transmission of sound.
JP2517760B2 (en) 1989-05-11 1996-07-24 新技術事業団 Water-soluble polymerized pharmaceutical preparation
KR940003548U (en) 1992-08-14 1994-02-21 김형술 Laundry dryer
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6403816B1 (en) 1997-09-30 2002-06-11 Dabur Research Foundation Betulinic acid derivatives having antiangiogenic activity, processes for producing such derivatives and their use for treating tumor associated angiogenesis
US5830964A (en) * 1997-12-18 1998-11-03 Isp Investments Inc. Vinyl pyrrolidone polymers substantially free of vinyl lactam monomers
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6617420B2 (en) * 2000-08-11 2003-09-09 Nippon Shokubai Co., Ltd. Process for reducing monomer content in N-vinyl compound polymers
US8545830B2 (en) 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
WO2007074476A1 (en) 2005-12-28 2007-07-05 Dabur Pharma Limited A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
AU2007333528B2 (en) * 2006-10-05 2013-10-17 The Johns Hopkins University Water-dispersible oral, parenteral, and topical formulations for poorly water soluble drugs using smart polymeric nanoparticles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0896025A2 (en) * 1997-08-05 1999-02-10 Stefano Gasparini Non-toxic plastic material having adsorbency and absorbency properties, and corresponding process for its manufacture
US6322817B1 (en) * 1999-02-17 2001-11-27 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof

Also Published As

Publication number Publication date
CA2635469A1 (en) 2007-07-05
US8927023B2 (en) 2015-01-06
EA017682B1 (en) 2013-02-28
EA200801563A1 (en) 2009-06-30
EP2172497A1 (en) 2010-04-07
EP2172497B1 (en) 2013-05-22
MY148575A (en) 2013-04-30
ES2425075T3 (en) 2013-10-11
AU2006329554B2 (en) 2013-01-10
BRPI0620745A2 (en) 2013-02-19
IL192423A0 (en) 2008-12-29
KR20080091158A (en) 2008-10-09
AR058866A1 (en) 2008-02-27
HK1123814A1 (en) 2009-06-26
MX2008008423A (en) 2008-09-23
US20130274211A1 (en) 2013-10-17
EP1971622A1 (en) 2008-09-24
US20090318661A1 (en) 2009-12-24
WO2007074476A1 (en) 2007-07-05
ES2375740T3 (en) 2012-03-05
CN101336256A (en) 2008-12-31
JP2009522251A (en) 2009-06-11
KR20130116954A (en) 2013-10-24
AU2006329554C1 (en) 2013-06-20
NZ569372A (en) 2011-10-28
EP1971622B1 (en) 2011-10-19
ATE529454T1 (en) 2011-11-15
US8338562B2 (en) 2012-12-25
AU2006329554A1 (en) 2007-07-05
ZA200806548B (en) 2010-02-24

Similar Documents

Publication Publication Date Title
CN101336256B (en) A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
RU2492872C2 (en) Water-dispersible oral, enteral and local compositions for poorly water-soluble drug preparations containing polymer nanoparticles improving properties thereof
RU2523714C2 (en) Polymer systems of delivering active substances
Tan et al. A novel MPEG-PDLLA-PLL copolymer for docetaxel delivery in breast cancer therapy
CN101501108A (en) Micelles for drug delivery
JP2003533492A (en) Drug composition in stable polymeric micelle form and method for producing the same
CN105963706B (en) A kind of branching HPMA copolymer-DOX conjugate and its preparation method and application
CN107789632A (en) A kind of active Brain targeting nanoscale medicine delivery system of T7 peptides modification and preparation method thereof
CA2835637A1 (en) Polymeric nanoparticles for drug delivery
Laskar et al. PEG based random copolymer micelles as drug carriers: the effect of hydrophobe content on drug solubilization and cytotoxicity
Chen et al. Thermal responsive micelles for dual tumor-targeting imaging and therapy
Pillai et al. Characterization and application of mixed micellar assemblies of PEO-PPO star block copolymers for solubilization of hydrophobic anticancer drug and in vitro release
Velluto et al. Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils
CN109762099A (en) A kind of polymer-antitumor medicine conjugate and its preparation method and application
CN104530438B (en) PH based on cholesterol modification responds polypeptide polymer and preparation method and application
Wu et al. Preparation of betulinic acid galactosylated chitosan nanoparticles and their effect on liver fibrosis
Zhang et al. The potential of poly [N-(2-hydroxypropyl) methacrylamide] via reversible addition-fragmentation chain transfer polymerization as safe nanocarrier
Sha’at et al. Evaluation of AML-VAL nanoparticles as combined therapy in cardiovascular disease
CN114377141B (en) Drug delivery carrier and anti-tumor application thereof
CN108542882B (en) Application of functional pharmaceutical composition
Hebels et al. Mechanistic Study on the Degradation of Hydrolysable Core-Crosslinked Polymeric Micelles
CN106265508A (en) The load paclitaxel targeting cross linked polymer micelle of a kind of DHA modification and preparation method and application
Dinh A novel solubilisation technique based on poly (γ-glutamic acid) for the delivery of amphotericin B and anticancer agents
WAI Stimuli sensitive core-shell nanoparticles for targetted drug delivery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123814

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1123814

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120328

Termination date: 20191226